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CHAPTER I 
 
INTRODUCTION 
 
The evolution of immune systems within complex, multi-cellular biological 
organisms has been fueled by the necessity of self-protection from parasitism in 
order to better ensure species propagation and survival. Given the sheer 
biomass of human pathogens (namely bacteria, viruses, fungi and helminths) 
and their extraordinary capacity to adapt to and thrive under intense selective 
environmental pressures, multi-cellular organisms have co-evolved a complex 
and intricate series of defense mechanisms in order to protect themselves from 
parasitic insults. Factors such as physical barriers (i.e. skin and mucosal 
surfaces), the fever response, soluble factors including anti-microbial enzymes 
secreted in saliva and liver-derived complement molecules as well as phagocytic 
and cytolytic cells such as polymorphonuclear (PMN) leukocytes and natural 
killer (NK) cells present within tissues provide humans with broad-ranging, 
immediate, yet transient protection from microbial pathogens. As a whole these 
components comprise a part of the human immune system termed natural or 
innate immunity. The innate immune system is referred to as such due to the fact 
that, 1) innate immunity is naturally present in humans at birth and in aseptic 
environments, and 2) its components are not selected for or enhanced by 
exposure to infectious microbes. The evolutionary conservation of innate 
immunity between humans and lower invertebrates underscores the critical role 
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for this system in providing protection from microbes. However, in addition to 
these lines of defense, higher vertebrates have uniquely developed additional 
measures to ward off microbial pathogens, namely the adaptive immune system.  
 
 
The human adaptive immune system tailors protective immune responses 
in a pathogen-specific manner 
 
The human adaptive immune system forms a unique and integral part of human 
immunity. The significance of the system in providing immunity to infectious 
diseases is underscored by a rare set of individuals carrying genetic deficiencies 
that clinically manifest as a disorder called severe combined immunodeficiency 
syndrome (SCID), which is characterized by the absence of most adaptive 
immune cells (1-7). These patients suffer from chronic and opportunistic 
infections and typically succumb to these onslaughts shortly (typically ~1 year) 
after birth. The cellular (B and T lymphocytes) and acellular (molecules secreted 
by lymphocytes called cytokines and antibodies) components of the adaptive 
immune system work in synergy with factions of the innate immune system to 
recognize, respond to and clear invading microorganisms. In this context, the 
adaptive immune system, once activated by invasive pathogens, feeds back to 
innate immune cells and tissues to activate phagocytosis (8) and complement-
mediated cytolysis of bacteria (9). Furthermore, adaptive immunity can mobilize 
innate immune cells to concentrate within tissues at sites of infection or at 
mucosal barriers that serve as entry portals for invading microbes (10, 11). In all 
respects, the adaptive and innate immune systems form a co-operative and non-
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redundant symbiosis within humans to guard against microbial insults. Yet while 
synergistic in its collaboration with innate immunity, the adaptive immune system 
has, in and of itself, evolved three hallmark features that differentiate it from 
innate immunity.  
 The first such distinguishing characteristic of adaptive immunity is the 
mode of pathogen recognition. Adaptive immune cells recognize pathogen-
specific molecules as presented by components of innate immunity, whereas the 
innate immune system senses invading pathogens in a more indiscriminant 
manner. Specifically, innate immune surveillance involves the use of germline-
encoded pattern recognition receptors (PRRs), one class of which is called toll-
like receptors (TLR). These receptors recognize broadly conserved components 
of bacterial and yeast cell walls, bacterial DNA motifs and double-stranded RNA 
from viruses (12-19). By contrast, the adaptive immune system has evolved more 
exquisite mechanisms of pathogen recognition. B and T lymphocytes recognize 
microbial antigens with remarkable specificity through the B cell 
receptor/antibody and T cell receptor (TCR), respectively (20, 21). However, size 
constraints within the human genome preclude encoding enough diversity within 
antigen receptors to specifically recognize the vast multitude of human 
pathogens.  Moreover, such a strategy of immuno-recognition by lymphocytes 
would render host cells incapable of recognizing microbes that can modify 
immunogenic epitopes when exposed to selective immune pressures. Thus, In 
order to generate a sufficiently broad-ranging protective repertoire of antigen 
receptors, B and T lymphocytes have evolved to somatically recombine a limited 
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set of germline-encoded antigen receptor gene segments through the activity of 
the recombinase activating genes (RAG) 1 and 2 (22-24). Indeed, antigen 
receptor gene rearrangement, along with other sources of diversification intrinsic 
within the process of V(D)J recombination (combinatorial and junctional) can 
generate greater than 109 possible receptors clonally expressed on the surface 
of human lymphocytes. Yet as with most facets of biology, the random 
generation of antigen receptors on lymphocytes is not without its faults, as it can 
give rise to self-reactivity and subsequent autoimmunity.  
 The adaptive immune system is further unlike the innate, in that it is highly 
dynamic in nature, capable of generating qualitatively distinct immune responses 
as shaped by the type of pathogen encountered. Two major types of adaptive 
immune responses that have been historically classified based on the cells and 
primary soluble mediators involved are humoral and cell-mediated immune 
responses. Humoral immunity involves the activation of B-lymphocytes (i.e. B 
cells) by microbial products present throughout the extracellular environment and 
thus, is typically generated against extracellular bacteria, bacterial toxins, fungi, 
parasitic helminths and surface-exposed portions of circulating viral particles. 
Once activated, B cells secrete antigen-specific antibodies into circulating body 
fluids or humor. Secreted antibodies can provide immune protection by 
opsonizing microbial cell-surfaces, thereby activating complement-mediated 
destruction (9, 25) and/or enhancing phagocytosis of the microbe via cellular 
recognition of antibody Fc regions (26, 27). Antibodies present on the surface of 
bacteria or pathogenic fungi can also inhibit adhesion to and transcytosis across 
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mucosal barriers (28) and can block viral or intracellular bacterial entry into and 
subsequent infection of host cells (28-31). Other antibodies, specifically of the 
IgE isotype, also serve as central mediators in protection against parasitic 
helminthes by promoting the release of vesicular elements stored within PMN 
basophils and eosinophils such as reactive oxygen/nitrogen intermediates and 
cytotoxic enzymes (32, 33). As with all types of immune responses, however, 
dysregulated production of antibodies can also cause pathophysiologies, such as 
atopic and allergic disorders (34). Moreover, antibody production against self-
antigens can lead to the pathogenesis of autoimmune systemic lupus 
erythematosis (SLE) and many other autoimmune disorders. 
 While B cells are responsible for the direct production of antibodies, a 
specific class of T-lymphocytes (i.e. T cells) called T helper (Th) cells, classified 
by the cell-surface expression of CD4, play a critical role in the mobilization and 
regulation of humoral responses. Effector Th cells are activated and secrete 
soluble cytokines upon interaction with B cells displaying microbial peptide 
antigens in the context of majorhistocompatability complex (MHC) class II 
molecules. The cytokines secreted by Th cells in turn instruct antibody class-
switch recombination in antigen-specific B cells (Table 1-1). The resultant plasma 
cells, which differentiate from activated B cells upon Th cell interaction, secrete 
antibodies of the IgG, IgA and IgE isotypes that most appropriately activate 
protective immune responses in a pathogen-specific fashion. 
 In addition to humoral immune responses, the adaptive immune system 
can also generate cell-mediated effector functions against pathogenic microbes. 
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Cell-mediated responses are primarily constituted by the activation of antigen-
specific CD8+ cytolytic T lymphocytes (CTLs) and IFNγ-producing Th cells in 
response to invasion by intracellular bacteria and viruses. CTLs receive 
activation signals in the context of microbial antigens presented on MHC class I 
molecules. MHC class I is expressed on nearly every human cell type in all 
tissues throughout the body and presents intracellular peptides proteolytically 
generated by cytosolic proteases, thus allowing CTLs to survey for and 
specifically identify infected host cells. Upon antigen recognition by CTLs, 
cytolytic enzymes including perforin and granzymes are released, directly killing 
infected cells as to limit the replication and systemic spread of intracellular 
pathogens (35). As with humoral immune responses, Th cells also play a pivotal 
role in the activation of CTLs as well as cytolytic natural killer (NK) cells through 
the production of IFNγ by effector and memory Th cells (Table 1-1). 
  The final distinguishing feature of adaptive immunity is the capacity to 
amplify pathogen-specific immune responses such that secondary responses to 
identical microbial antigens are more rapid and greater in magnitude than the 
primary response. This feature is termed immunological memory and is the 
fundamental underpinning of vaccinations and naturally acquired long-term 
immunity. Immunological memory is achieved through the generation and long-
term maintenance of antigen-specific plasma B cells and memory T cells, even in 
the absence of antigen (36-40). In the context of memory, appropriate 
development of memory Th cells is of keen importance given their vital roles in 
mobilizing and regulating both humoral and cell-mediated facets of adaptive 
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immunity. Thus, the development, function and interaction of Th cells with 
microbial pathogens are critical steps in determining the outcome of pathogenic 
infections.  
  Collectively, these hallmark features of adaptive immunity are essential to 
orchestrating successful defense strategies against diverse sets of human 
pathogens. However, a highly malleable system if not tightly regulated, can lose 
self-discriminatory capacities and thus instigate autoimmunity. Simply stated, 
autoimmune responses are a failure of the cardinal purpose of immune systems: 
to react to and protect against foreign parasites (non-self) without damaging host 
cells or tissues (self). And while entire anatomical organs, namely long bone 
marrow and the thymus, facilitate the selection of non-self reactive mature B and 
T cells, respectively (41-43), autoreactivity remains a common cause of human 
morbidity and mortality. Interestingly, autoimmunity is, without exception, a 
manifestation of misguided adaptive, not innate, immune activation. This is likely 
due to the fact that innate immunity is “older” in evolutionary terms than the 
adaptive immune system and that innate immunity is strictly encoded within the 
germline of the organism, which is inherently non-autoreactive. Nonetheless, 
evolution of the adaptive immune system in the face of possible autoimmunity 
speaks to the immense selective pressure exerted on higher vertebrates by 
pathogenic microbes and the premium placed on a dynamic adaptive immune 
system. 
 
 
 
 
8 
T helper cells differentiate into heterogeneous effector and memory cells to 
regulate adaptive immunity 
 
The adaptive immune system is a hierarchy of individual cell types that 
sequentially communicate in order to organize and concentrate protective 
responses against invading pathogens. CD4+ Th cells play a central role in 
orchestrating the quality and efficacy of immune responses through their 
secretion of effector cytokines. Thus, elucidating the molecular mechanisms 
involved in Th cell differentiation to effector and memory Th cell subsets and the 
resultant acquisition of effector function has broad-reaching implications in 
understanding how qualitatively distinct immune responses are generated and 
modulated. Such insight also provides an important framework for vaccine design 
and the development of novel therapeutic strategies to enhance anti-microbial 
immunity and pacify immunopathologies. 
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Table 1-1: Cytokine production by Th cells regulates immunity. 
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Generation and function of central and effector memory Th cells 
Antigen-specific effector and memory Th cells differentiate from clonal naïve 
precursor (TN) cells in the periphery via antigen-dependent activation during 
pathogenic infection. Yet not all memory Th cells are created equal. Rather, 
memory cells are a complex and heterogeneous population, whose constituents 
form a dynamic network ready to adapt and strike against any external threats to 
the organism. TN cells activated by cognate antigen differentiate into 
compartmentalized pools of antigen-specific Th cell subsets, termed central and 
effector memory cells that are both functionally and phenotypically 
distinguishable (38, 44). It is ultimately the type and quality of the antigen-specific 
memory Th cell repository generated during a primary immune response, which 
in turn shapes anti-microbial effector responses and forms the basis of 
immunological memory. It is noteworthy that antigen-experienced CD8+ CTLs 
also differentiate into central and effector memory T cell subsets (40, 45). 
However, per the focus of the research detailed herein the following overview 
focuses on the CD4+ subset of T cells. 
Central memory (TCM), and effector memory (TEM) T cells were first 
identified and are canonically differentiated based on their distinct effector 
functions and migratory properties (44, 46). TCM cells are highly similar to TN cells 
in that they express receptors necessary to circulate through draining peripheral 
lymph nodes (CCR7+, CD62L+), display high levels of T cell receptor excision 
circles (TRECs) and exhibit weak effector function upon antigenic stimulation (44, 
47). Nonetheless, TCM cells represent an antigen-primed population of memory 
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Th cells functionally distinct from TN cells. Specifically, TCM cells more rapidly 
respond to antigenic stimulation than naïve cells, are more sensitive to limiting 
concentrations of antigen and co-stimulatory molecules and produce greater 
quantities of IL-2 and up-regulate CD40L to a greater extent upon activation as to 
provide efficient help to B cells (48-51). TCM cells also survive, proliferate and 
acquire the ability to produce effector cytokines in response to stimulation with 
homeostatic cytokines (IL-2, IL-7, IL-15) unlike TN cells (46). The molecular 
mechanism underlying antigen-independent TCM differentiation to TEM cells 
remains poorly understood. 
Recently it has been discovered that the TCM cell repertoire can be further 
sub-divided into non-polarized or pre-effector TCM cell populations based on 
chemokine receptor expression profiles. Truly non-polarized TCM cells that 
completely lack effector function express CXCR5, which serves to draw the cells 
to B cell follicles via its chemokine ligand CXCL13 and provide help to B cells 
during humoral activation (52, 53). Conversely, CXCR5- TCM cells that attain 
expression of the inflammatory chemokine receptors CXCR3 or CCR4 represent 
a pre-effector lineage of cells that, while lacking immediate effector function can 
differentiate in antigen-dependent and independent mechanisms to Th1 or Th2 
TEM cells in response to TCR and cytokine stimulation, respectively (47).  
In contrast to TCM cells, TEM cells lose the ability to traffic to secondary 
lymphoid organs (CCR7-, CD62L-) and up-regulate pro-inflammatory chemokine 
receptors (44), allowing them to extravasate to inflamed peripheral tissues and 
secrete robust levels of polarized effector cytokines upon antigen recognition (54, 
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55). TEM cells respond to activation signals by rapidly synthesizing effector 
cytokines, but produce little IL-2, proliferate poorly and are highly susceptible to 
activation-induced cell death (AICD) compared to TN and TCM cells (49-51, 56).  
The physiologic function of and relationship between TCM and TEM cells 
remains an area of intense investigation. While the strong effector functions of 
TEM cells suggest a more central role for the subset during immune activation, 
both TCM and TEM cell populations contain antigen-specific clones in roughly 
equivalent ratios across a wide variety of pathogens (47). Moreover, TCM cells 
have longer half-lives than their TEM counterparts (56-58), and more actively re-
populate immunocompromised mice in adoptive transfer experiments (45, 59), 
suggesting TCM cells are indeed a vital component of long-lived immunologic 
memory. The remarkable capacity of TCM cells to further develop into TEM cells 
upon re-stimulation through TCR or cytokine receptors, taken together with 
studies showing that TCM cells are phenotypically more “naïve” than TEM cells, 
have higher levels of TRECs and display greater functional plasticity, all strongly 
suggest that TCM cells represent an earlier stage of T cell differentiation than TEM 
cells and implies a precursor-product relationship (44, 46, 47, 60). Such a 
relationship, however teleologically intuitive, is not without controversy. 
Longitudinal clonotypic analyses of the TCR repertoires of murine and human 
TCM and TEM subsets have suggested it may also be possible for TEM cells to 
subsequently populate the TCM compartment. Regardless, a scenario involving 
the progressive differentiation of TN – TCM – TEM cells would allow for the rapid 
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generation and maintenance of a diverse repertoire of antigen-specific memory T 
cells in the face of constantly evolving human pathogens (40, 44, 46) (Fig. 1-1).  
 
The Th1/Th2 dichotomy 
In addition to yielding diverse antigen-specific memory cell populations that either 
lack or acquire effector activity, TN cell differentiation also generates distinct sets 
of TEM cells that display polarized effector function and lymphoid homing 
propensities, termed T helper type 1 (Th1) or type 2 (Th2) cells. On one hand, 
Th1 cells secrete IFNγ, thereby activating macrophages as well as CTL and NK 
cell cytolysis to eliminate intracellular pathogens. In contrast, Th2 cells secrete 
IL-4, IL-5 and IL-13, which orchestrate humoral responses and activate PMN 
eosinophils against helminthic parasites and extracellular microbes (61-63). 
Importantly, negative cross-regulation between the two effector subsets is a 
critical feature for mounting effective immune responses while preventing 
immunopathologies that stem from skewed effector Th cell responses, such as 
autoimmune diseases and allergic inflammation.  
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Figure 1-1: Development of central and effector memory Th cell subsets. 
TN cells activated by antigen presenting cells (APCs) integrate cytokine and 
TCR/co-stimulatory signals, undergo clonal expansion and are programmed to 
differentiate to either central or effector memory subsets. TCM cells are further 
sub-divided into follicular Th cells (CXCR5+), pre-Th1 (CXCR5- CXCR3+) or pre-
Th2 (CXCR5- CCR4+) TCM cells. Pre-Th1 and –Th2 differentiate to Th1 and Th2 
TEM cells upon stimulation with homeostatic cytokines. TEM cell populations are 
comprised of highly polarized Th1 and Th2 cell subsets. Differentiation of TN cells 
to TCM cells is driven by short exposure to antigenic stimulation in the absence of 
polarizing cytokines whereas TEM cell differentiation occurs under optimal TCR 
stimulation in the presence of influential cytokine signals. 
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TN cell differentiation to effector subsets involves the integration of a 
complex series of extracellular stimuli delivered from APC during antigen 
recognition and activation. The dose of antigen (48, 64, 65), nature of the peptide 
ligand (66-68), and source of co-stimulation (69, 70) have all been reported to 
influence TN cell differentiation. However, cytokine signals present during T cell 
activation are paramount in driving TN cell polarization to effector subsets (63, 71, 
72). Of importance, IL-12, IL-18, IL-27 and IFNγ can all promote Th1 
differentiation, whereas IL-4 and IL-13 promotes Th2 cell development. As such, 
mice deficient in these cytokines, their receptors and downstream signaling 
components display perturbations in TN cell differentiation (73-78). Ultimately, the 
combinatorial signals emanating from the T cell and cytokine receptors culminate 
in the induction of the master transcription factors T-bet and GATA-3, which in 
turn specify the fate of TN cell differentiation to Th1 or Th2, respectively (79-81) 
(Figure 1-3). 
 There are two phases of TN cell differentiation that are both spatially and 
temporally distinct.  The first phase takes place in peripheral lymph nodes as TN 
cells recognize antigen-pulsed APC, receive instructive activation signals, and 
commence differentiation. Subsequent clonal expansion and migration to areas 
of tissue inflammation ensues. The resultant lineage-committed Th1 or Th2 cells 
respond to secondary challenge of antigen by secreting lineage-specific 
cytokines independent of polarizing signals, a process referred to as cytokine 
memory that involves the lineage-specific programmed alteration of chromatin 
structure at specific cytokine gene loci. Th1 cells stabilize the IFNγ gene locus in 
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a transcriptionally active state, as opposed to Th2 cytokine gene loci, which 
remain silent (82-85). Paradoxically, Th2 cells maintain IL-4, IL-5 and IL-13 gene 
loci in states competent for stable expression, with the IFNγ locus being set in 
heterochromatin (82-85). Such epigenetic changes resulting in cytokine memory 
implies stability within the differentiation programs of Th cells, yet more recent 
evidence demonstrates human Th1 and Th2 cells are capable of modifying their 
effector functions during secondary encounters with antigen. Th2 cells have been 
shown to retain responsiveness to IL-12, producing IFNγ upon TCR re-
stimulation in its presence (83, 86). Moreover, a TCR-transgenic CD4+ memory T 
cell population has been shown capable of secreting distinct patterns of effector 
cytokines depending on the nature of the TCR re-triggering (68). While 
precipitated by extracellular cues, the reprogramming of entrenched Th1 and Th2 
cells involves the induction of master transcription factors from the opposing 
lineage. Work from our lab detailed herein has demonstrated that lineage-
committed Th1 or Th2 cells can be directly reprogrammed by ectopic expression 
of GATA-3 or T-bet, respectively, irrespective of exogenous cytokine signals (60). 
Indeed, an adaptable memory T cell response, exhibiting plasticity in the context 
of antigen re-exposure, could be a highly beneficial strategy against constantly 
evolving pathogens and suggest that long-term human T cell memory could be 
modulated by either novel vaccine or gene therapy approaches. 
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Figure 1-2: Molecular regulation of Th1/Th2 differentiation. 
Activation of TN cells by TCR stimulation in the presence of IL-12 or IFNγ signals 
promotes the specific up-regulation of T-bet and subsequent Th1 differentiation. 
Contrarily, IL-4 presence during TCR stimulation of TN cells activates GATA-3, 
thereby orchestrating differentiation to the Th2 lineage. Lineage-committed Th1 
and Th2 cells reveal their polarized effector functions upon re-stimulation in the 
absence of exogenous cytokines (see methods, chapter II, cytokine detection). 
Th1 cells are IFNγ+IL-4- whereas Th2 cells produce IL-4 but not IFNγ.  
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Polarized Th1 and Th2 cells were originally identified and are canonically 
characterized based on polarized cytokine production. In addition to cytokines, 
however, chemokines and their cognate receptors play pivotal roles in adaptive 
immunity by directing lymphoid trafficking to various immune organs and tissues 
(11). Indeed, more recent work has uncovered that Th1 and Th2 cells also 
express distinct combinations of chemokine receptors on their cell surface. 
Specifically, CXCR3 and CCR5 are expressed at higher levels on Th1 cells (87-
90), whereas CCR3, CCR4, and CCR8 are preferentially expressed on Th2 cells 
(87, 91). The recently identified prostaglandin D2 receptor (CRTH2) (92), 
although not a member of the chemokine receptor family, is also highly Th2-
specific and has been shown to hold chemotactic activity for this subset (93). 
Differential expression of chemokines by activated phagocytes, stromal cells, 
endothelial and epithelial cells within inflamed tissues and lymphoid organs can 
thus direct tissue-specific trafficking of Th1 and Th2 cells to areas where their 
effector functions would be most effective (11). Whereas much is now known 
regarding the differential function of human Th1 and Th2 cells, the mechanisms 
governing their differentiation remain poorly resolved. 
 
T-bet and GATA-3: masters of their domains 
During the initial activation of TN cells by APC, both type 1 (IFNγ) and type 2 (IL-
4) cytokines are transiently produced within the first 24-48 hours. Subsequently, 
instructive antigen receptor and cytokine signals induce and stabilize the 
expression of either T-bet or GATA-3, which in turns specifies the fate of TN cell 
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differentiation to Th1 or Th2 cells, respectively. TBX21, or T-box expressed in T 
cells (T-bet) is a member of the T-box family of transcription factors and a 535 
amino acid protein. Structurally, T-bet contains a prominent 189 amino acid 
stretch that makes up a highly conserved T-box DNA-binding domain. In T cells, 
T-bet is induced in a STAT-1-dependent mechanism upon IFNγ signaling during 
Th1 differentiation (94) and strongly promotes IFNγ production and expression of 
the signaling β-2 subunit of the IL-12 receptor (IL-12Rβ2), while repressing Th2 
differentiation (80, 94, 95). Indeed, T-bet-deficient mice exhibit a profound defect 
in mounting Th1 immune responses and spontaneously develop airway 
hypersensitivity, a pathologic feature consistent with enhanced Th2 development 
and onset of asthma (96). Likewise, human asthmatic patients carrying a 
naturally occurring T-bet variant protein (H33G), which confers increased Th1 
and decreased Th2 cytokine production in vitro, respond significantly better to 
corticosteroid treatment (97). Moreover, short-interfering RNA (siRNA)-mediated 
silencing of T-bet in murine Th cells inhibits Th1 cell development and 
suppresses Th1 cell-mediated immunopathologies in an autoimmune mouse 
model of multiple sclerosis (MS) (98). Interestingly, knockout studies 
demonstrate that whereas T-bet is required for IFNγ production in Th and NK 
cells, it is largely dispensable in other IFNγ-producing cell types such as CTLs 
(99).  
By contrast to T-bet, GATA-3 is a zinc finger protein and member of the 
GATA family of transcription factors (GATA-1-6), which all play critical roles in the 
development, differentiation and function of multiple cell types and tissues (100). 
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GATA-3 was originally identified based on its capacity to bind the promoter of all 
4 TCR genes (alpha, beta, gamma and delta) and enhance their expression 
during thymocyte development (101, 102). More recently, however, GATA-3 has 
been shown to be instrumental in the development and function of Th2 cells in 
the periphery. GATA-3 is constitutively expressed at low, basal levels within 
mature, antigen-inexperienced TN cells and is specifically induced in response to 
IL-4/STAT-6 signaling during TCR-activation. In turn, GATA-3 undergoes STAT6-
independent auto-amplification, trans-activates the expression of IL-5, directs 
chromatin remodeling to stabilize transcription of IL-4 and IL-13 and renders 
developing Th cells refractory to Th1 polarizing cytokines (103). Moreover, 
ectopic expression of GATA-3, even in developing or fully differentiated Th1 
cells, induces Th2 cytokine production, reduces IFNγ secretion and promotes 
chromatin remodeling of the IL-4 promoter locus (104-107). Conversely, gene 
deletion or siRNA-mediated silencing of GATA-3 in mature Th cells leads to a 
profound disruption in Th2 differentiation and effector function (108, 109).  
Structurally, GATA-3 contains 443 amino acids and is comprised of two 
centralized C4-type zinc-finger motifs that mediate DNA binding (100, 110, 111). 
The zinc-finger domain of GATA-3, along with an adjacent C-terminal stretch of 
basic residues, serve to mediate DNA binding to the consensus element 
(A/T)GATA(A/G), a highly conserved property amongst all GATA transcription 
factors (110-113). The GATA zinc-fingers also mediate protein-protein 
interactions with other transcription factors, most notably AP-1, FOG, CBP/p300 
and NFAT (114-122). Outside its DNA-binding zinc-fingers, GATA-3 has putative 
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trans-activation domains that contain multiple acceptor sties for post-translational 
modifications. Indeed, GATA-3 has been shown to be targeted for 
phosphorylation and acetylation (123-125). However, the manner in which post-
translational modifications modulate GATA-3 activity during Th cell differentiation 
remains uncertain. 
While definitive master regulators of Th cell differentiation, it has become 
increasingly evident that T-bet and GATA-3 do not act in isolation to carry out the 
Th1 and Th2 differentiation programs. Indeed, activation of Th cells through the 
TCR and cytokine signals elicits an extraordinarily complex series of signal 
transduction events that result in the activation of many other transcription factors 
(aside from T-bet and GATA-3) important for the activation, proliferation, and 
differentiation of T cells. Thus, the unique combination of transcription factors 
activated during the primary antigenic stimulation of TN cells synergistically co-
ordinates a specialized program of gene expression that determines if, and what 
type of effector functions will be acquired. 
 
Specific aims 
The differentiation of antigen-specific effector and memory Th cells is a critical 
step in the mobilization and regulation of human immune responses to invading 
pathogens. Yet the molecular mechanisms that govern Th cell differentiation 
remain poorly defined. As such, the central goals of this thesis are 1) to further 
define the molecular mechanisms whereby T-bet and GATA-3 program TN cell 
differentiation to Th1 and Th2 subsets, 2) to characterize the roles of T-bet and 
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GATA-3 in maintaining the effector function and lymphoid homing potentials in 
differentiated memory Th cells, and 3) to understand how key human pathogens 
interact with, and manipulate Th cell function to evade the human immune 
response. 
With respect to how human TN cells differentiate into functionally and 
phenotypically distinct effector/memory cells, we favor a model wherein the 
central goal of Th cell differentiation is to acquire a potent, and specialized set of 
effector functions. Therefore, we hypothesize that cells within the TN, TCM and 
TEM subsets all represent unique stages of Th cell differentiation, with TEM cells 
signifying the end point of Th cell differentiation. Thus, in order to gain further 
insight into how T-bet and GATA-3 regulate human Th cell differentiation and to 
further define the relationship between naïve and memory subsets, in chapter II 
we determine the capacities of the master transcription factors to reprogram the 
functional properties of human memory Th cell subsets. 
While the pivotal role of T-bet in Th1 cell development is clear, the 
requirement for T-bet in maintaining the effector function of lineage-committed 
Th1 cells has yet to be determined. To this end, in chapter III we develop a stable 
form of RNA interference (RNAi) using a lentiviral-based system to ask whether 
silencing of T-bet expression in fully differentiated Th1 cells perturbs their pre-
existing effector function. We posit that the key role of T-bet in effector and 
memory Th cells is not to directly regulate IFNγ transcription, but is rather to 
maintain Th1 effector function by suppressing Th2 reprogramming.  
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We also aim to further define how GATA-3 regulates gene expression 
during Th2 differentiation. GATA-3 binds to DNA via its conserved dual zinc-
finger domain in order to program Th2 differentiation. Yet little is known as to 
whether this domain is sufficient to direct Th2 cell development. As such, in 
chapter IV we invoke the use of a heterologous GATA transcription factor, GATA-
1, which shares conserved DNA-binding propensities with GATA-3, yet lacks 
significant sequence similarity in N- and C-terminal regions of the gene/protein. 
Using this approach, we design experiments to determine if the highly conserved 
zinc-finger domain of GATA-1 is sufficient to redundantly regulate Th2 cell 
polarization, akin to GATA-3. 
The expression of T-bet and GATA-3 during Th cell differentiation 
ultimately determines the acquisition of effector function as well as the 
expression of chemokine receptors that mediate Th cell recruitment to inflamed 
tissues. Intriguingly, chemokine receptor expression can also influence Th cell 
susceptibility to human immunodeficiency virus (HIV)-1. Specifically, this is 
achieved through the differential expression of the major HIV-1 co-receptor 
CCR5 (126-128), which is expressed at higher levels on Th1 than Th2 cells. 
Moreover, CCR5 promoter regions contain several GATA-binding sites (129, 
130), suggesting a potential CCR5 regulatory activity by GATA-3. However, this 
potential role of GATA transcription factors in the regulation of CCR5 gene 
expression in primary human Th cells has yet to be explored. In chapter IV, we 
seek to directly link the expression of GATA transcription factors in human Th 
cells to the expression of CCR5 and, in turn, to the susceptibility of Th cells to 
24 
HIV-1 infection. Moreover, utilizing GATA-1 and GATA-3 we dissect the 
fundamental regulatory features of GATA transcription factors that determine the 
expression of CCR5. Indeed, the identification of transcription factors that directly 
regulate the expression of CCR5 could lead to new anti-retroviral therapies 
aimed at down-regulating CCR5 expression in individuals afflicted with HIV-1. 
A second important human pathogen that evades the immune system is 
Helicobacter pylori (H. pylori), a bacterium that establishes a persistent infection 
in the gastric mucosa of more than half of the human population (131, 132). 
Clearance of H. pylori has been suggested to be dependent on the successful 
generation of H. pylori-specific effector and memory Th cells (133-135), which in 
turn requires efficient activation-dependent clonal expansion of developing Th 
cells via the autocrine production of IL-2. Perhaps not surprisingly, H. pylori has 
been recently shown to inhibit T cell activation through the activity of its 
vacuolating cytotoxin (VacA) (136, 137). To better understand this mechanism of 
VacA-mediated inhibition of human Th cell activation, in chapter V we more 
specifically determine the cellular effects of VacA intoxication and perform 
valuable structure/function analyses to characterize the manner in which VacA 
inhibits Th cell activation. These key studies provide the fundamental framework 
to understanding how H. pylori evades the immune response and persists within 
its human host. Moreover, as H. pylori infection is associated with peptic ulcer 
disease and gastric cancers, this work may aid the development of new therapies 
against H. pylori. 
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The transcriptional regulation of Th cell differentiation by T-bet and GATA-
3 ultimately determines the quality of adaptive immune responses that 
determines if the host response will be protective, ineffective or pathologic in 
nature. Thus, the key questions addressed herein are of keen importance to 
decode the differentiation programs of human Th cells and have broad-reaching 
therapeutic implications. The knowledge gained from these studies provides 
novel insight into the roles and function of T-bet and GATA-3 during human Th 
cell differentiation. Moreover, these findings may aid in the development of novel 
vaccine-based or therapeutic strategies to manipulate Th cell differentiation and 
function in order to fine-tune human immune responses against pathogenic 
microbes or pacify immunopathologies stemming from skewed effector and 
memory Th cell function. 
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CHAPTER II 
 
GENETIC REPROGRAMMING OF HUMAN T CELLS REVEALS FUNCTIONAL 
PLASTICITY IN HUMAN T CELL DIFFERENTION 
 
Abstract 
 
Activation of naïve T cells (TN) through the TCR and cytokine signals directs their 
differentiation into effector or memory subsets with different cytokine profiles. 
Here, we tested the flexibility of human Th1 or Th2 differentiation by forced 
expression of transcription factors T-bet and GATA-3. Ectopic expression of T-
bet and GATA-3 in freshly isolated human TN cells resulted in their differentiation 
to a Th1 and Th2 phenotype, respectively, in the absence of polarizing cytokines. 
Introduction of GATA-3 into lineage-committed Th1 cells induced the expression 
of Th2-specific cytokines (IL-4 and IL-5) and chemotactic receptors (CCR4, 
CRTH2). However, these cells partially maintained their Th1-specific profile (IFNγ 
and IL-12Rβ2 expression). Conversely, expression of T-bet in differentiated Th2 
cells caused a more profound switch to the Th1 phenotype, including up-
regulation of CXCR3 and down-regulation of CCR4 and CRTH2. Interestingly, 
similar to the TN subset, TCM cells were also largely programmed towards Th1 or 
Th2 effector cells upon expression of T-bet and GATA-3, respectively. However, 
expression of these transcription factors in TEM cells was much less influential on 
cytokine and chemokine receptor expression profiles. Our results reveal 
remarkable plasticity in the differentiation programs of human memory T cells 
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and have important implications in understanding the molecular mechanisms of 
human T cell differentiation and for devising novel therapeutic strategies aimed at 
immunomodulation of skewed effector T cell responses. 
 
Introduction 
 
Protective immune responses against pathogens are mediated by functionally 
distinct subsets of antigen-specific effector T cells, termed Th1 or Th2 cells, 
which display distinct cytokine profiles. The Th1 subset secretes IFNγ and is 
instrumental in mobilizing cell-mediated immunity to eliminate intracellular 
pathogens. In contrast, Th2 cells secrete IL-4, IL-5 and IL-13, which orchestrate 
humoral responses against helminthic parasites and extracellular microbes (61-
63). Cross-regulation between the Th1 and Th2 subsets is critical for mounting 
effective immune responses and for preventing immunopathologies, such as 
those associated with allergy and autoimmune diseases. Cytokine signals are 
paramount in driving the effector fate of naïve T lymphocytes (63, 71). Of key 
importance, IL-12 or IFNγ signals drive Th1 differentiation, whereas IL-4 
promotes Th2 cell development (61, 63, 71). Signals emanating from the T cell 
and cytokine receptors culminate in the activation of transcription factors, which 
in turn specify the fate of naïve T cell differentiation.   
Induction of the transcription factors GATA-3 and T-bet are critical for 
differentiation of naïve T cells into Th2 and Th1 cells, respectively (79-81). 
GATA-3 is a zinc finger protein that is preferentially expressed during the course 
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of Th2 differentiation in response to IL-4 signals. In turn, GATA-3 trans-activates 
the expression of IL-5 and directs chromatin remodeling to stabilize the 
production of IL-4 and IL-13 (79, 104, 138-141). Several studies have 
demonstrated that GATA-3 expression is sufficient to direct differentiation into 
Th2 cells (96, 105-107, 142-144). GATA-3 over-expression in murine Th1 cells 
has been shown to result in the production of Th2 cytokines, as well as a 
decrease in IFNγ secretion and chromatin remodeling of the IL-4 locus (105-107, 
145). GATA-3 expression in Th2-lineage committed cells is followed by induction 
of the transcription factor c-maf which synergistically controls the expression of 
IL-4 (146-148). In addition, GATA-3 also potently trans-activates IL-5 and IL-13 
expression (140, 149, 150).  In contrast, T-bet, a member of the T-box family of 
transcription factors, is a master regulator of Th1 lineage commitment (80, 99). T-
bet is induced by STAT-1 mediated signals and strongly promotes IFNγ and IL-12 
receptor-β2 (IL-12Rβ2) expression during Th1 cell differentiation while repressing 
Th2 differentiation (80, 94, 95, 151). Indeed, T-bet deficient mice exhibit a 
profound defect in mounting Th1 immune responses (99) and ectopic expression 
of T-bet in murine Th2 cells directs trans-activation of IFNγ, as well as the up-
regulation of IL-12Rβ2 (80, 94, 95). 
Polarized Th1-and Th2-subtypes also express distinct chemokine receptor 
profiles. Specifically, CCR3, CCR4, and CCR8 are preferentially expressed on 
Th2 cells (87). In contrast, CXCR3 and to a lesser extent CCR5 are expressed at 
higher levels on Th1 cells (87).  The recently identified prostaglandin D2 receptor 
(CRTH2) (92), although not a member of the chemokine receptor family, is also 
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highly Th2 cell specific and has been shown to have chemotactic activity for this 
subset (93). Differential expression of chemokines and their receptors within 
inflamed tissues and lymphoid organs could direct tissue specific trafficking of 
Th1 and Th2 cells to areas where their effector functions would be most effective. 
Little is known as to how human T cell differentiation into Th1 or Th2 subsets is 
regulated. The stability of cytokine profiles in differentiated effector and memory 
T cell subsets are also not well understood. While a recent study demonstrated 
that lineage-committed memory T cell subsets are responsive to cytokine signals 
of the opposing lineage (83),  the direct roles of T-bet and GATA-3 in these 
reprogramming processes remain unclear. The molecular mechanisms that 
coordinately regulate chemokine receptor expression during T cell differentiation 
also remain poorly understood. To address these key questions we utilized a 
lentiviral transduction system (152) to express the Th1- or Th2-specific 
transcription factors T-bet or GATA-3 in primary human T cells at different stages 
of differentiation. We show that TN and TCM human T cells display a high level of 
flexibility in their cytokine and chemotactic receptor expression profiles as 
directed by GATA-3 or T-bet. In contrast, effector T cells are more limited in their 
ability to reprogram their cytokine and chemokine receptor expression. This 
multi-faceted plasticity of human T cells suggests potential strategies for 
manipulating immune responses during immunological diseases or vaccine 
development. 
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Materials and Methods 
 
Lentiviral vectors  
Construction of HIV-derived vectors (HDV) was previously described (152). To 
create a bicistronic vector that expressed a gene-of-interest and a marker gene 
we sub-cloned the murine CD24 (HSA) gene that also contained an upstream 
internal ribosome entry site (IRES, obtained from Clontech) into the HDV vector. 
Briefly, both IRES and HSA sequences were PCR-amplified and triple ligated into 
NotI and XhoI sites of HDV in place of the nef gene. Full length GATA-3 cDNA 
was obtained from the Incyte Genomics clone repository. The T-bet gene was 
PCR-amplified from a human Th1 specific cDNA library using T-bet specific 
primers and subcloned into the HDV vector. All constructs were confirmed by 
sequencing of the insert regions.  
 
Purification of resting human T cells   
PBMC were separated from neonatal placental cord blood or from adult blood by 
Ficoll (Pharmacia) centrifugation. Resting CD4+ T cells were purified as 
previously described (152).  Briefly, CD4+ T cells were positively sorted using 
anti-CD4 Dynabeads followed by detachabead removal of the beads (Dynal). 
Purified CD4+ cells were then incubated with anti-CD8, anti-HLA-DR, anti-CD14, 
and anti-CD45RO (BD Biosciences), followed by Dynabeads conjugated with 
goat-anti-mouse IgG (Dynal) to deplete bead-bound pre-activated or memory T 
cells as well as residual CD8+ T cells, monocytes, or dendritic cells. After final 
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purification, the cells were 99.5% CD4+CD45RA+RO- as determined by FACS 
analysis. To purify cells that were infected with HDV constructs expressing the 
reporter protein mouse CD24 (HSA), T cells were incubated with biotin-
conjugated anti-mouse-HSA (1 ug/ml) for 30 minutes on ice. Cells were washed 
twice with PBS, and subsequently incubated with streptavadin-conjugated MACS 
beads (Miltenyi biotech) for 20 minutes on ice. After washing, HSA+ cells were 
sorted using a magnetic sorter (MACS system from Miltenyi biotech). To purify 
central and effector memory T cells, purified CD4+ cells were first stained with 
anti-CD45RA antibodies followed by goat-anti-mouse IgG conjugated to 
magnetic beads (Dynal) and CD45RA+ naïve T cells were removed. The negative 
portion, which typically is 98% CD45RO+RA-, was stained with an anti-CCR7 
antibody (R&D systems) and sorted into CD45RO+CCR7+ (central memory) and 
CD45RO+CCR7- (effector memory) T cells using a flow cytometer sorter 
(Vanderbilt University flow cytometry facility).  
 
T cell activation and differentiation  
Differentiation of naïve T cells was accomplished via TCR stimulation using anti-
CD3 (OKT3, ATCC) and anti-CD28 (BD Biosciences) antibodies in the presence 
or absence of polarizing cytokines.  Flat-bottom 96 well plates were coated with 
10 ug/ml goat-anti-mouse IgG (Caltag) for one hour at 37˚C.  Wells were washed 
twice with PBS and coated with 1 ug/ml anti-CD3 for an additional hour at 37˚C. 
After washing to remove unbound CD3 antibodies, T cells were added to 
antibody coated wells with soluble anti-CD28 (1 ug/ml) and the following cytokine 
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and blocking antibody combinations: human recombinant IL-4 (R&D Systems, 20 
ng/ml) and neutralizing anti-IFNγ (R & D Systems, 2.5 ug/ml) antibody, or human 
recombinant IL-12 (R & D Systems, 30 ng/ml) and neutralizing anti-IL-4 (R & D 
Systems, 0.5 ug/ml) antibody.  Cells were removed from activation signals after 
48-72 hours and expanded in recombinant IL-2 (Chiron, 200 U/ml) containing 
media. The culture media used in all experiments was RPMI supplemented with 
10% fetal calf serum, as described before (152).    
 
Virus production and infections 
VSV-G pseudotyped, replication incompetent HIV-1 particles were generated as 
previously described (152).  Briefly, HEK-293T cells were transfected with HDV 
and VSV-G plasmids.  Supernatants were collected at 48 hours post transfection, 
filtered through 0.45 um filters, and stored at –80˚C. Cytokine or TCR-activated T 
cells were infected in flat-bottom 96-well plates at a 3-5 multiplicity of infection 
(MOI).  In some experiments, cells inoculated with virus were centrifuged for 1 
hour at 2000 rpm to enhance infections as described (153). 
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FACS Analysis   
T cells were stained with the relevant antibody on ice for 45 min in PBS buffer 
containing 2% FCS and 0.1% sodium azide. Cells were then washed twice, fixed 
with 1% paraformaldeyde, and analyzed with a FACSCalibur® four color 
cytometer, using the CellQuest program.  Live cells were gated based on forward 
and side scatter properties and analysis was performed using FlowJo software 
(Tree Star). The following anti-human antibodies were used for staining: CD3, 
CD4, CD8, CD45RO, CD45RA, CD14, CCR4, CXCR3, IL-12Rβ2 (all from BD 
Biosciences), CCR7 (R&D sciences) and a murine antibody against CD24 (HSA) 
cell surface antigen (Pharmingen). The CRTH2 antibody used for these 
experiments has been previously described (92).  
 
Real time PCR  
Total RNA from resting and activated Th cells was isolated using Qiagen RNeasy 
Midi Kit (Qiagen) following the manufacturer’s instructions. RNA samples were 
treated with Qiagen DNase (Qiagen) to remove any contaminating DNA and 
subjected to reverse transcription using Life Technologies SuperScript First-
Strand Synthesis System (Invitrogen) following the manufacturer’s instructions. 
The cDNA was then used to perform real-time PCR with the TaqMan universal 
PCR Master Mix (Roche) in a Model 7900 ABI Sequence Detection System. RNA 
samples were normalized using GAPDH primers and probe (Applied 
Biosystems). The sequences of the primers and probes are as follows:   
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GATA-3 forward: GGACGAGAAAGAGTGCCTC  
GATA-3 reverse: TGGGACGACTCCAGCTTCA  
GATA-3 probe: FAM-AGGTGCCCCTGCCCGACAGC-BHQ  
T-bet forward: GCTGAGTTTCGAGCAGTCAGC  
T-bet reverse: AGTAGGACATGGTGGGCCC  
T-bet probe: FAM-TGAAGCCTGCATTCTTGCCCTCTGC-BHQ 
c-maf forward: AAGAGGCGGACCCTGAAAA  
c-maf reverse: CGTGTCTCTGCTGCACCCT 
c-maf probe: FAM-CGGCTATGCCCAGTCCTGCCG 
 
Cytokine detection  
For intracellular cytokine analysis, T cells were stimulated with PMA (Sigma, 50 
ng/ml) and Ionomycin (Sigma, 0.5 ug/ml) in the presence of .67ml/ml GolgiStop 
(Pharmingen). The cells were incubated for 4-6 hours at 37˚C followed by fixation 
and permeabilization using a commercial kit (Pharmingen) according to 
manufactures instructions.  Subsequently, cells were stained with the following 
antibodies against human cytokines: APC-conjugated anti-IFNγ, PE-conjugated 
anti-IL-4 and, in some experiments, with PE-conjugated anti-IL-13 and APC 
conjugated anti-IL5 (all from Pharmingen). For detection of secreted cytokines, T 
cells were stimulated with anti-CD3 (OKT-3, ATCC) coated plates in the 
presence of soluble anti-CD28 (Pharmingen, 1 ug/ml) for 18 hours. Supernatants 
were assayed using a cytometric bead array (CBA) according to the 
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manufacturer’s instructions (BD Biosciences) (154), and analyzed using CBA 6-
bead analysis software (BD Biosciences).  
 
Western blot analysis of T-bet and GATA-3 expression 
CD4+ T cells transduced with either the control HDV, HDV.GATA-3, or HDV.T-bet 
were lysed at 5x107 cells/ml in SDS lysis buffer containing: 0.25 M Tris base 
(Sigma), 8% SDS, 4% β-mercapthoethanol (EM Science) and protease inhibitor 
cocktail (Boehringer Mannheim). About 30ug of protein lysates were fractionated 
on 10% SDS-PAGE gels (Invitrogen) and transferred onto PVDF membranes 
(Bio-rad). Blots were probed with anti-T-bet (Santa Cruz, N-15) and anti-GATA-3 
(Santa Cruz, HG3-31) antibodies followed by HRP-conjugated anti-goat IgG (for 
T-bet antibody) or anti-mouse IgG (for GATA-3 antibody) (Jackson laboratories). 
Blots developed using west pico luminal/peroxide solutions (Bio-Rad) and 
autoradiographed (Amersham). To normalize for protein content, the membranes 
were stripped using a commercially available stripping solution (Bio-rad) for 5 min 
at 37 C and 7 min at 25 C. Stripped membranes were then probed with anti-β-
actin (Santa Cruz, I-19) antibody followed by anti-mouse IgG-HRP (Jackson 
laboratories). 
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Results 
 
Differentiation of TN cells by the ectopic expression of GATA-3 and T-bet. 
Human naive T cells can be polarized to differentiate into Th1 or Th2 cells upon 
stimulation through the TCR and by either IL-12 or IL-4, respectively. To 
establish Th1 and Th2 lineage committed cells from neonatal cord blood, we 
isolated CD4+ TN cells and activated with anti-CD3 and anti-CD28 antibodies in 
the presence IL-12 or IL-4. Activated TN cells were expanded in IL-2-
supplemented media for 8-10 days, and effector populations were either probed 
for expression of the Th2-specific cell-surface molecule, CRTH2, or re-stimulated 
through the TCR for determination of cytokine profiles.  TN cells differentiated into 
Th1 (IFNγhighIL-4lowCRTH2neg) or Th2 (IFNγnegIL-4highCRTH2high) effector cells in 
the presence of the appropriate cytokine milieu (Fig. 2-1A).  
We next asked whether stable expression of T-bet or GATA-3 in highly 
purified human TN cells could override the requirement for Th1 and Th2 
polarizing cytokine signals during Th1 and Th2 cell differentiation, respectively.  
In order to ectopically introduce these transcription factors into TN cells, we used 
an HIV-derived lentiviral vector (HDV) system that allows for highly efficient and 
stable gene transduction in primary human T cells (152).  To monitor the 
functional effects of T-bet or GATA-3 expression in primary human T cells, we 
utilized HDV constructs that bicistronically express a marker gene (HSA). TN cells 
were infected with HDV, HDV.GATA-3, or HDV.T-bet viruses at the time of CD3 
and CD28 stimulation. Activated and transduced cells were expanded for 8 days 
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and HSA+ cells were purified. Upon reactivation, cells expressing T-bet or GATA-
3 displayed typical Th1 or Th2 cytokine profiles, respectively, similar to TN cells 
polarized with cytokines (Fig. 2-1B). Furthermore, GATA-3 transduced cells 
expressed high levels of CRTH2, similar to Th2 cells polarized by IL-4 signals 
(Fig. 2-1A and 2-1B). These experiments establish a genetic system that can be 
effectively used to program human T cell lineage commitment. 
To directly assess the level of expression of GATA-3 and T-bet in HDV-
transduced primary T cells, we conducted western blot experiments. We 
detected high levels of GATA-3 or T-bet in T cells transduced with lentiviral 
vectors expressing these genes as compared to cells transduced with HDV alone 
(Fig. 2-2A and 2-2B). In addition, we also performed real time PCR analysis, 
which demonstrated at least 10-fold increase in transcript levels both for T-bet 
and GATA-3 in cells transduced with these genes (data not shown). 
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Figure 2-1: Differentiation of TN cells expressing T-bet or GATA-3. 
(A) Human TN cells purified from neonatal cord blood or adult PBMC were 
activated through the TCR in the following conditions: 1) Th0: media alone 2) 
Th1: IL-12 and neutralizing α-IL-4, or 3) Th2: IL-4 and neutralizing α-IFNγ. Cells 
were activated with α-CD3 and α-CD28 antibodies and expanded in IL-2-
containing media for 8-10 days. These cells were then re-stimulated with PMA 
and Ionomycin in the presence of monensin (4 hours) for intracellular cytokine 
staining. CRTH2 cell surface expression was determined via FACS analysis.  (B) 
Human TN cells isolated as described above were again activated through the 
TCR in media without polarizing cytokines, but containing the following viral 
supernatants HDV, HDV.GATA-3, or HDV.T-bet. Cells were expanded for 8-10 
days and cytokine and CRTH2 expression profiles were assessed as detailed in 
(A). The transduced cells were identified by co-staining for HSA expression. 
These data represent one out of four experiments with naïve T cells purified from 
different adult and neonatal blood samples. 
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Figure 2-2. Expression of T-bet and GATA-3 in transduced cells.  
(A) Purified CD4+ T cells were activated and transduced as detailed in the figure 
1B legend, either with HDV, HDV.GATA-3 or HDV.T-bet viruses.  Cells were 
expanded for 8 days in IL-2-suplemented media and sorted for HSA expression. 
These cells were then lysed and western blot analysis was performed for: A) 
GATA-3 and B) T-bet expression using specific antibodies. The membranes were 
stripped and subsequently probed for β-actin (lower panels). The data are 
representative of two separate western blot experiments using transduced cells 
obtained from different adult blood donors. 
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Reprogramming of lineage-committed Th1 and Th2 human T cells by ectopic 
expression of GATA-3 or T-bet 
 
We next designed experiments to ask whether the phenotype of activated human 
TN cells that have already committed to Th1 or Th2 effector states can be 
reversed upon ectopic expression of GATA-3 or T-bet, respectively. The Th1 and 
Th2 cells generated from TN cells (Fig. 2-1) were transduced with HDV.GATA-3, 
HDV.T-bet, or the control HDV (Fig. 2-3). After three days post-infection, 
transduced Th1 and Th2 cells were either analyzed for cell surface expression or 
stimulated through TCR to determine their cytokine profile. While expression of 
GATA-3 in committed Th1 cells induced IL-4 and IL-5 to varying degrees and 
induced CRTH2 expression, it had little effect on IFNγ production and IL-12Rβ2 
cell-surface expression (Fig. 2-3). In contrast, expression of the Th1-specific 
transcription factor T-bet in committed Th2 effector cells greatly increased IFNγ 
production and IL-12Rβ2 (Fig. 2-3). T-bet expression also almost completely 
extinguished IL-5 expression and resulted in a 10-fold reduction of IL-4 
production by Th2 cells (Fig. 2-3). In addition, expression of T-bet in Th2 cells 
abrogated CRTH2 cell-surface expression (Fig. 2-3). These data suggest early-
lineage-committed human T cells retain flexibility in reprogramming their effector 
functions. 
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Figure 2-3. Ectopic expression of GATA-3 or T-bet in committed Th1 or Th2 cells directs the reprogramming of 
effector functions.   
Freshly purified human naïve CD4+ T cells were activated through the TCR in either Th1 or Th2 polarizing cytokine 
conditions as described in the Figure 1 legend.  Cells were expanded for 13 days in IL-2 supplemented media and 
subsequently transduced with the control HDV, HDV.GATA-3, or HDV.T-bet. Cells were sorted 3 days post-transduction 
based on HSA expression (for intracellular cytokine analyses and CBA experiments). Cell-surface CRTH2 expression was 
determined as described in the Figure 1 legend using unsorted cells.  These data are representative of three experiments.
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We then asked whether this flexibility in the programs of cytokine 
production during Th cell differentiation extends to the regulation of chemokine 
receptor expression.  Committed Th1 and Th2 cells transduced with either the 
control HDV or an HDV expressing the opposing transcription factor were 
harvested and cell surface chemokine receptor expression was ascertained 
through flow cytometric analyses. Genetically unaltered Th1 cells, as well as 
those transduced with the control HDV expressed a chemokine receptor profile 
characteristic of Th1 cells (CCR4-, CXCR3+).  Indeed, Th1 cells in which GATA-3 
was ectopically expressed significantly down-regulated CXCR3 expression while 
inducing high-level CCR4 expression (Fig. 2-4). On the contrary, lineage-
committed Th2 cells not transduced or those transduced with HDV displayed the 
expected Th2-specific chemokine receptor expression profile (CCR4+, CXCR3-) 
(Fig. 2-4).  Whereas, Th2 cells transduced with HDV.T-bet up-regulated CXCR3 
expression, and down-regulated CCR4 expression (Fig. 2-4).  These data imply 
that lineage-committed effector T cells can be directly reprogrammed by T-bet or 
GATA-3 to change their chemokine receptor pattern and thus their migratory 
preferences. 
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Figure 2-4. Lineage-committed Th1 and Th2 cells modify their chemokine 
receptor expression profiles upon GATA-3 and T-bet ectopic expression. 
Similar primary human Th1 and Th2 cell lines were generated via TCR activation 
as described in the figure 3 legend. Transduced cells for these experiments were 
left unsorted and chemokine receptor expression profiles were determined via 
flow cytometric analyses 3 days post transduction, with transduced cells being 
separated by co-staining for HSA. These results are representative of three 
experiments using cells from different donors. 
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Flexibility in effector functions of human memory T cell subsets 
TN cells activated through TCR-signaling acquire the ability to produce cytokines 
and gain other effector functions (155). A portion of effector T cells become long-
lived antigen-specific memory T cells. Recently, human memory T cells I have 
been shown to consist of two subsets, termed central memory (TCM) and effector 
memory (TEM) T cells (44). TCM cells, defined by the expression of CCR7, express 
lymphoid homing receptors and lack robust effector functions. However, TCM cells 
can rapidly respond to pathogens or cytokines and mature into TEM cells, which 
lose the expression of CCR7, acquire tissue-homing receptors, and secrete large 
quantities of cytokines (44). The ability of GATA-3 and T-bet to change the 
cytokine profile of lineage-committed T cells led us to investigate whether the 
effector functions of TCM and TEM cells could be modified by expression of these 
transcription factors. The TCM and TEM cells were purified based on expression of 
CCR7 and CD45RO as previously described (44). To confirm that the 
CD45RO+CCR7+ and CD45RO+CCR7- subsets represent TCM and TEM cells 
respectively, we stimulated these cells through the TCR and determined their 
cytokine production. As previously reported (44), we found that TEM cells 
secreted higher quantity of cytokines (TNFα, IFNγ, IL-4 and IL-5) as compared 
TCM cells (data not shown). Highly purified TCM and TEM cells were then 
transduced with GATA-3 and T-bet expressing HDV and activated with anti-CD3 
and anti-CD28. Cells were expanded for 8 days in IL-2 and re-stimulated through 
the TCR to evaluate their effector functions. Expression of GATA-3 in TCM cells 
resulted in a 5-fold increase in cells that were IL-4+IFNγ-, typical of a Th2 
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phenotype, whereas T-bet expression greatly increased the number of IFNγ+IL-4- 
TCM cells as compared to non-transduced or control HDV-transduced TCM cells 
(Fig. 2-5A). Transduction of GATA-3 into TEM cells also resulted in an increase of 
IL-4 producing cells (2-fold), albeit this was at a lower magnitude than in TCM cells  
(Fig. 2-5A).  Ectopic expression of T-bet in TEM cells caused most to express 
IFNγ, similar to that observed for TCM subset. However transduction of T-bet into 
TEM cells was less effective in suppressing IL-4 expression (Fig. 2-5A). We also 
examined the intracellular expression patterns of two other Th2-specific 
cytokines, IL-5 and IL-13, in GATA-3 or T-bet expressing TCM and TEM cells (Fig 
2-5B).  GATA-3 over-expression resulted in a 2-fold increase in IL-5+ and IL-13+ 
TCM and TEM cells (Fig. 2-5B).  In contrast, expression of T-bet greatly reduced 
the number of IL-5 producing cells, and resulted in a two-fold decline in IL-13+ 
TCM and TEM T cells (Fig. 2-5B).   
Concomitant analysis of CRTH2, revealed that GATA-3 expression in TCM 
cells, mimicked the effects observed in TN cells, by resulting in an approximate 
10-fold induction of CRTH2+ cells, whereas GATA-3 transduction into TEM cells 
only resulted in a 2-fold increase in CRTH2 expression (Fig. 2-6A). In contrast, T-
bet expression in both human memory T cell subsets resulted in near abrogation 
of CRTH2 cell-surface expression (Fig. 2-6A).   
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Figure 2-5. Human central and effector memory T cells transduced with T-
bet and GATA-3 display flexible cytokine profiles.   
CD45RO+RA- memory T cells were sorted via FACS into TCM (CCR7+) and TEM 
(CCR7-) cells. The two memory T cell populations were then activated for 24 
hours through the TCR via antibody stimulation (see methods), and infected with 
viruses containing either the control HDV, HDV.GATA-3, or HDV.T-bet. After 8 
days of expansion, intracellular expression of the cytokines A) IL-4 and IFNγ, B) 
IL-5 or IL-13, were determined by flow cytometry as described in the methods. 
For these experiments transduced cells were left unsorted, but were co-stained 
with an anti-HSA antibody and the HSA positive populations were gated on for 
analysis of intracellular cytokine production. 
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We next determined whether the chemokine receptor profiles of TCM and 
TEM cells could also be modified by the ectopic expression of GATA-3 and T-bet, 
similar to lineage-committed effector Th1 and Th2 cells (Fig 2-3). Similar to TN 
cells, in the presence of GATA-3, CCR4 levels were highly induced in TCM cells 
while CXCR3 expression was lower (Fig. 2-6B). T-bet expression in TCM cells 
resulted in the up-regulation of CXCR3, while conversely down-regulating CCR4 
expression (Fig. 2-6B). Introduction of GATA-3 and T-bet into TEM cells also had 
an effect on chemokine receptor expression, however these effects were much 
more modest as compared to TN and TCM subsets (Fig. 2-6B). Taken together, 
these results show that the effector functions and chemokine receptor expression 
profiles of human memory T cells can be genetically reprogrammed through the 
expression of master transcription factors. However, the functional plasticity 
observed in effector/memory T cells progressively diminishes as cells move 
through their differentiation.   
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Figure 2-6. Chemokine receptor expression profiles in human TCM and TEM 
subsets are modified by ectopic expression of T-bet and GATA-3.  
Human central and effector memory cells were purified, activated, and 
transduced with HDV alone, HDV.GATA-3, or HDV.T-bet as in the figure 5 
legend. Following expansion, unsorted cells were stained with antibodies against 
either: A) CRTH2, B) CCR4 or CXCR3 in conjunction with an anti-HSA antibody 
to gate on transduced populations. The percent of positive cells for the 
appropriate chemokine receptor is shown. Results are representative of one of 
four experiments using T cell subsets from distinct adult donors. 
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Discussion 
 
We demonstrate that lineage-committed and primary human memory T cells, can 
be genetically reprogrammed towards Th2 or Th1 type cells by the transcription 
factors GATA-3 and T-bet, respectively. Transduction of GATA-3 in TN and TCM 
cells induce cytokine and chemokine receptor expression patterns ascribed to 
Th2 cells.  However, GATA-3 fails to significantly down-regulate IFNγ production 
and IL-12Rβ2 expression in cells already committed to the Th1 lineage, and in 
the TEM subset. Conversely, T-bet directs TN and TCM human T cells to a Th1 
phenotype, while it was less effective upon expression in the TEM subset.  These 
data suggest a progressive loss of flexibility as T helper cells proceed from naïve 
to effector memory stages of their differentiation. 
The acquisition of effector functions and more rapid recall responses to 
antigens during T cell differentiation form the basis of immunological memory. 
The TCM and TEM subsets of human memory T cells have distinct effector 
functions and migratory properties (44, 156). TCM cells express receptors 
necessary for lymphoid organ trafficking, and display only moderate effector 
function upon antigenic stimulation. Conversely, TEM cells lose the ability to traffic 
to lymphoid organs and up-regulate pro-inflammatory chemokine receptors, while 
secreting robust levels of effector cytokines.  TCM cells can further develop into 
TEM cells upon re-stimulation through TCR or cytokine receptors, thus 
maintaining a diverse repertoire of antigen-specific memory cells (44, 156). We 
have shown that the cytokine profiles of TCM and, to a lesser extent, TEM cells can 
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be reprogrammed by constitutive expression of T-bet or GATA-3. These findings 
support our hypothesis that TCM cells represent an antigen-primed subset, which 
is capable of modifying its lineage commitment upon antigenic stimulation to 
generate new waves of TEM cells. On the other hand, one would expect 
differentiated TEM cells, which have already been programmed to mount specific 
responses to an invading pathogen, to lack the adaptability to environmental 
cues that TCM cells exhibit. However, our findings demonstrate that even the 
cytokine secretion in TEM cells can be partially modified, particularly in response 
to forced T-bet expression. Indeed, an adaptable memory T cell response, 
exhibiting plasticity in the context of antigen re-exposure, could be a highly 
beneficial strategy against constantly evolving pathogens. This hypothesis is also 
supported by a previous report which demonstrated distinct patterns of cytokine 
production were elicited in a TCR-transgenic mouse model (68). Our results also 
suggest that long-term human T cell memory could be modulated by either novel 
vaccine approaches or genetic manipulation of T cell differentiation programs.  
Signaling from IL-12Rβ2 or the IL-4R is thought to be a primary mode of 
induction of T-bet or GATA-3, respectively, during TCR-stimulation of naïve T 
cells (157). In our studies we bypassed these receptor signals by over-
expressing transcription factors. Our observations extend recent findings that the 
effector functions of human memory T cell subsets exhibit malleability in 
response to IL-4 signals (83).  Although, IL-12Rβ2 expression is not detectable 
on Th2 cells and was found to be non-functional in murine studies (Fig. 2-3 and 
refs (158-161)), recent results suggest that Th2 committed human T cells can 
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respond to IL-12 signals ((86) and unpublished data)). In addition, it is possible 
that, independent of IL-4 or IL-12 signals, either the strength of antigen-receptor 
activation or other co-stimulatory signals could act to induce GATA-3 or T-bet in 
Th1 or Th2 polarized memory T cells, respectively (48, 66, 69, 70). 
Consistent with our conclusions, a recent report by Messi et al. 
Demonstrated that cytokine signals are capable of re-directing cytokine profiles in 
human effector and memory T cell subsets (33), suggesting functional cytokine 
receptors are maintained on lineage-committed T cells to some extent.  In this 
study a subset of memory T cells did not change their effector status in the 
presence of opposing cytokines.  It was not clear whether this resistance to re-
commit was maintained through the regulation of cytokine receptor levels, 
downstream signaling modules, or the induction or activity of opposing 
transcription factors.  Indeed, our results show that ectopic expression of T-bet 
and GATA-3 can modify effector function and lymphoid homing receptor 
expression in lineage-committed effector and memory T cells. However, similar 
to findings by Messi et al., we observed a population of memory T cells were 
resistant to T-bet or GATA-3-mediated re-programming. This resistant subset 
grew in size as cells transitioned from TCM to TEM cells. Because we bypassed 
receptor signals by ectopically expressing programming transcription factors, the 
likely mechanism for the progressive loss of flexibility within the memory 
population are heritable epigenetic changes at effector gene (cytokine, 
chemokine receptor) loci.  Messi et al.’s study supports this hypothesis by 
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demonstrating that lineage-committed memory cells failed to modify their histone 
acetylation patterns of cytokine genes, as compared to TN and TCM cells (33). 
Our results also show that ectopic expression of T-bet not only induces 
IFNγ and IL-12Rβ2 expression, but can also function to repress expression of 
Th2 cytokines in lineage committed Th2 cells, whereas GATA-3 was not effective 
in suppressing IFNγ secretion. One possible explanation for this observation 
could be due to epigenetic changes such as demethylation of cytosine 
nucleotides in CpG pairs (162) and/or histone-tail modifications (82) which allow 
for structural rearrangements at appropriate cytokine gene loci.  T-bet was shown 
to be critical for robust histone acetylation of the IFNγ  promoter (163). It is 
possible that T-bet may also help in recruitment of histone deacetylases to Th2 
cytokine gene loci thereby suppressing transcription. In support of this, it was 
found that the IL-4 promoter and enhancer were hyperacetylated in T-bet–
deficient Th1 cells (164). Another possibility could be due to the down-regulation 
of other Th2-specific transcription factors such as c-maf (120, 146, 165, 166). 
Indeed transduction of T-bet into resting or activated Th2 cells also resulted in a 
3 to 6-fold reduction in c-maf gene expression as assessed by real-time PCR 
analysis (data not shown). In contrast to the potency of T-bet, the failure to fully 
reprogram lineage committed Th1 cells into Th2 cells by GATA-3 may be due to 
a requirement for c-maf and perhaps other as yet-to-be-discovered transcription 
factors (81). 
In addition to cytokine production by effector and memory human T cells, 
chemokines and their cognate receptors play a pivotal role in adaptive immunity. 
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We have shown that primary human TN, TCM and Th1 lineage-committed T cell 
subsets transduced to express GATA-3 greatly up-regulated CCR4, while 
partially down-regulating CXCR3 expression. T-bet over-expression, on the other 
hand, resulted in an opposite expression pattern.  However, TEM cells were 
largely resistant to modulation of CCR4 and CXCR3, consistent with the notion of 
less flexibility within this subset. Our data show that functional plasticity of early 
lineage-committed effector and TCM cells extends to the control of lymphoid 
homing receptors. These findings are significant in understanding how the 
selective expression of chemokine receptors by Th1 and Th2 cells allows for their 
preferential recruitment to peripheral tissues and sites of inflammation (167-169). 
Indeed, CXCR3 ligands, such as IP-10, MIG, and I-TAC, as well as the CCR4 
ligands MDC, and TARC are expressed by a number of cell types and are 
produced in peripheral tissues during inflammatory reactions (170-172), Hence, 
we propose that functional modifications in TCM subset upon induction of T-bet 
and GATA-3 could lead to a re-structuring of the lymphoid trafficking framework 
during recall responses to antigens.  
Another Th2-specific receptor, CRTH2, upon binding to its ligand, PGD2, 
serves in the selective recruitment of Th2 cells (92, 93). Our results clearly show 
that GATA-3 greatly up-regulates cell-surface CRTH2 expression, whereas T-bet 
expression promotes its down-regulation in cells at all stages of differentiation.  
Interestingly, some cells, such as mast cells, that are potent producers of 
prostaglandins, including PGD2, also express high levels of IL-4 when stimulated 
(173). Thus, CRTH2 may play an as yet unidentified role in the amplification of 
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Th2 differentiation by bringing Th2 cells into proximity with high levels of IL-4 in 
the periphery. It is also possible that prostaglandins themselves may signal 
through GATA-3 induced CRTH2 to serve as an amplifier, facilitating 
differentiation into the Th2 lineage. Additionally, CRTH2 expression may play a 
role in quenching Th1 responses by helping to recruit IL-4 producing Th2 cells to 
the site of inflammation.  
In conclusion, our findings reveal a remarkable degree of plasticity in the 
differentiation programs of human T cells. In particular, we show that lineage-
committed effector T cells, as well as antigen-specific central memory T cell 
subsets, retain the ability to modify their cytokine and chemokine receptor 
profiles in response to expression of opposing transcription factors. These 
findings suggest that during the course of an immune response antigen-specific 
memory T cells can modulate their effector functions and lymphoid trafficking 
properties according to the cytokine milieu or other signals provided by antigen 
presenting cells. Our results may also have implications in designing therapeutic 
interventions aimed at ameliorating immunopathologies stemming from 
misbalanced memory T cell responses, such as allergic asthma or autoimmune 
diseases.  In addition, the feasibility of genetically modifying naïve human T cells 
can be utilized for the rapid functional validation of genes involved in T helper cell 
differentiation. 
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CHAPTER III 
 
RNA INTERFERENCE IN HUMAN T HELPER CELLS REVEALS T-BET 
EXPRESSION IS REQUIRED FOR TH1 DEVELOPMENT BUT DISPENSABLE 
FOR MAINTAINING LINEAGE-COMMITTED EFFECTOR FUNCTION 
 
Abstract 
 
T-bet is a master transcription factor required for the differentiation of Th1 
effector and memory cells from naïve T (TN) cell precursors. Upon differentiation, 
Th1 cells display high-level production of the type 1 cytokine IFNγ independent of 
polarizing cytokine signals when re-exposed to antigen. Whether T-bet 
expression in lineage-committed Th1 cells is required for the maintenance of 
effector function remains uncertain. To address this fundamental question of T 
cell immunobiology we developed a lentiviral-based system allowing for the 
stable introduction of T-bet short hairpin RNAs (shRNA) into primary human T 
helper (Th) cells that specifically silences T-bet expression. Here we detail the 
generation of a RNA interference (RNAi) vector and selection of functionally 
active T-bet shRNAs. Utilizing this unique genetic tool, we demonstrate that the 
expression of T-bet is required in developing Th1 cells for optimal acquisition of 
IFNγ-producing capacity (i.e. Th1 differentiation), but is dispensable for 
maintaining effector function in differentiated Th1 effector cells. These results 
demonstrate the utility of RNAi as a tool to decode the differentiation programs of 
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human Th cells and lends further insight into the role of T-bet during Th cell 
differentiation. 
 
Introduction 
 
T-bet is a member of the T-box family of transcription factors and is the master 
transcriptional regulator of Th1 differentiation (80, 99). In chapter II we 
demonstrate that T-bet expression, even in lineage-committed Th2 cells or 
human memory Th cell subsets, reprograms their effector function and 
chemokine receptor expression patterns to a Th1 profile (60). In contrast to T-bet 
over-expression, genetic deficiency or siRNA-mediated silencing of T-bet in mice 
causes a profound defect in mounting Th1 immune responses and attenuates the 
pathogenesis of a Th1 cell-mediated immunopathology in an autoimmune mouse 
model of multiple sclerosis (98, 99). Indeed, the critical and instructive role of T-
bet during Th1 cell development is underscored by previous reports 
demonstrating that ectopic expression of T-bet can program Th1 differentiation 
even in T cells genetically deficient in IL-12 signaling (95).  
However important in the differentiation of and IFNγ production by Th1 
cells, T-bet does not appear to be required in other IFNγ-producing cell lineages, 
including CD8+ CTLs (99, 174). These key findings suggest that IFNγ can be 
regulated in both T-bet-dependent and independent manners. However, whether 
lineage-committed Th1 cells that produce IFNγ upon re-exposure to antigen in 
the absence of polarizing cytokines require maintained T-bet expression has yet 
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to be determined. Here we utilize RNA interference (RNAi) of T-bet expression to 
further elucidate the role of this master transcription factor in maintaining Th1 cell 
effector function in differentiated effector cells. 
The phenomenon of RNA interference (RNAi) was originally discovered in 
studies using transgenic plants wherein the introduction of specific DNA 
transgenes was capable of inactivating expression of the endogenous homolog 
and was originally called co-suppression (175-177). Subsequent pioneering 
studies in plants, as well as in the nematode C. elegans and drosophila more 
faithfully characterized RNAi as the sequence-specific, post-translational 
inhibition of mRNA expression mediated by 19 to 25 base-pair oligonucleotides 
(oligos) termed short interfering RNA (siRNA) (178-183).  More recently, it has 
become clear that RNAi is an evolutionarily conserved mechanism of regulating 
gene expression during cell development and embryogenesis and also plays an 
important role in immune protection (184-188).  
Mechanistically, siRNAs mediate mRNA degradation through the 
activation of the cellular RNAi machinery without triggering intrinsic inflammatory 
reactions to double-stranded RNA (dsRNA) as mediated by type I interferons 
(177). siRNAs are generated from dsRNA molecules that are derived from 
endogenously expressed cellular microRNAs (188), vector derived short-hairpin 
RNAs (shRNAs) (189, 190) or from infectious viruses during replication (184, 
191). dsRNA precursors are approximately 70-nucleotides in length and are 
enzymatically processed into siRNAs (19 to 25 base pairs). The enzyme 
responsible for siRNA production was originally discovered in cell-free drosophila 
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extracts to be an RNase III enzyme that is now called Dicer (183, 192, 193). 
Once produced in cells siRNAs bind to cognate cellular or viral mRNA molecules 
in a sequence-specific manner and target their enzymatic degradation by an 
effector nuclease called RNA-induced silencing complex (RISC) (194-196). One 
remarkable feature of RNAi is that only a few molecules of locally-administered 
dsRNA in plants, nematodes and drosophila can be exponentially amplified, 
become systemic and can even be passed on to progeny (177, 178, 197). 
However, it has become increasingly evident that this process, termed systemic 
interference, is not conserved amongst higher vertebrates and mammals. Thus, 
dsRNA transfection into human cells only results in the transient expression of 
siRNAs and subsequent gene silencing, thereby limiting the utility of RNAi in 
mammalian cells (198, 199). To circumvent this obstacle, we developed a 
lentiviral-based method allowing for the stable expression of siRNA in primary 
human Th cells. 
Here we describe the successful development and expression of T-bet-
specific siRNA in primary human Th cells. Utilizing this important genetic tool, we 
show that siRNA-mediated silencing of T-bet expression in TN cells driven to 
differentiate to the Th1 lineage severely impairs acquisition of IFNγ production 
and expression of Th1-associated chemokine receptors.  In contrast, however, 
lineage-committed Th1 effector cells were not altered in their IFNγ-producing 
potentials upon T-bet silencing. These novel findings suggest that whereas 
maintained T-bet expression is obligatory for Th1 development from naïve 
precursors, it is dispensable for the maintenance of Th1 effector function upon-
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lineage commitment. Our results further define the role of T-bet in Th1 
development and provide novel insight into the genetic regulation of IFNγ in 
human Th cells.  
 
Materials and Methods 
 
Generation of lentiviral vectors for RNAi 
The HIV-derived self-inactivating lentiviral vector FUGW (200) was modified for 
siRNA expression by blunt-end ligation of a Gateway cloning cassette 
(Invitrogen) at the unique Pac I site upstream of the human Ubiquitin C 
promoter. DNA oligonucleotide duplexes encoding shRNA cassettes were cloned 
into pENTR/U6 (Invitrogen) downstream of the U6 promoter site according to the 
manufacturer’s instructions.  The U6-shRNA cassettes were then shuttled into 
FUGW by LR recombination (Invitrogen). The fidelity of shRNA sequences was 
confirmed after the final cloning reaction via sequencing. All shRNA cassettes 
contain stems of 21-bp organized in a 5’-sense-loop-antisense-3’ orientation with 
the following loop sequence: 5’-AGAGCTTG-3’. The target sequences for the 
constructs used in this study are as follows: 
T-bet (#2 – Figure 3-2) 5’-GTTGTGGTCCAAGTTTAATCA-3’ 
 
NegControl   5’-GTTATTCGCGCGAATAACGTT -3’ 
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Purification of human Th cells 
PBMC were separated from neonatal placental cord blood or from adult blood by 
Ficoll (Pharmacia) centrifugation. Resting CD4+ T cells were purified as 
previously described (152) via anti-CD4 Dynabeads followed by detachabead 
removal of the beads (Dynal). After final purification, the cells were 99.5% 
CD4+CD3+ as determined by FACS analysis. GFP+ siLENT-transduced cells 
were sorted via flow cytometric cell sorting (FACSAria - Vanderbilt University flow 
cytometry facility). 
 
T cell activation and differentiation  
Activation and differentiation of purified human CD4+ Th cells was accomplished 
via TCR stimulation using anti-CD3 (OKT3, ATCC) and anti-CD28 (BD 
Biosciences) antibodies in the presence or absence of polarizing cytokines as 
described (60). Briefly, 96 well plates were coated with 10 ug/ml goat-anti-mouse 
IgG (Caltag) for one hour at 37˚C. Wells were washed twice with PBS and coated 
with 1 ug/ml anti-CD3 for an additional hour at 37˚C. After washing to remove 
unbound CD3 antibodies, T cells were added to antibody-coated wells with 
soluble anti-CD28 (1 ug/ml) in either non-polarizing or Th1-polarizing cytokine 
conditions as previously described (60). Cells were removed from activation 
signals after 48 hours and expanded in recombinant human IL-2 (Chiron, 200 
U/ml) supplemented media. The culture media used in all experiments was RPMI 
supplemented with 10% fetal calf serum as described before (152). 
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Virus production and infections  
VSV-G pseudotyped, replication-incompetent HIV-1 particles were generated as 
previously described (152).  Briefly, HEK-293T cells were triply transfected with 
siLENT, gag/pol and VSV-G plasmids. Supernatants harvested 48 hours post 
transfection time points were pooled and subjected to 0.45 micron PVDF filtration 
(Millipore) followed by ultracentrifugation at 25,000 rpm for 2.5 h at 4C in a 70Ti 
fixed-angle rotor (Beckman). Viral pellets were resuspended in 1mM EDTA/ PBS 
by overnight shaking. Titers were determined by serial infections of Jurkat T cells 
with newly made virus and resolving the percent GFP-positive (transduced) cells 
48 hour after infection via FACS analysis. For siLENT vector transduction 
experiments, TCR-activated Th cells were infected in flat-bottom 96- or 24-well 
plates at a 3-8 multiplicity of infection (MOI) and cells inoculated with virus were 
centrifuged for 1 h at 2000 rpm to enhance infections as described (153). 
 
FACS analysis 
T cells were stained with the relevant antibody on ice for 30-45 min in PBS buffer 
containing 2% FCS and 0.1% sodium azide. For monitoring cell-surface 
expression of chemokine receptors, T cells were incubated with un-conjugated 
antibodies for 20 minutes at room temperature, washed twice and incubated with 
PE-conjugated secondary antibodies on ice for 30-45 minutes. Cells were then 
washed twice, fixed with 1% paraformaldeyde, and data was acquired with a 
FACSCalibur® four color cytometer, using the CellQuest program. Live cells were 
gated based on forward and side scatter properties and analysis was performed 
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using FlowJo software (Tree Star). The following anti-human antibodies were 
used for staining: CD3, CD4, CCR4, CCR5, CXCR3 and CCR4 (all from BD 
Biosciences).  
 
 
 
Real time PCR  
Total RNA from resting and activated Th cells was isolated using Qiagen RNeasy 
Mini Kit (Qiagen) according to manufacturer’s instructions. RNA samples were 
treated with DNase (Qiagen) to remove contaminating DNA and were then 
subjected to reverse transcription using Life Technologies SuperScript First-
Strand Synthesis System (Invitrogen) following the manufacturer’s instructions. 
The cDNA was then used to perform real-time PCR with the TaqMan universal 
PCR Master Mix (Roche) in a Model 7900 ABI Sequence Detection System. RNA 
samples were normalized using GAPDH primers and probe. The sequences of 
the T-bet primers and probe are as follows:  
T-bet forward: GCTGAGTTTCGAGCAGTCAGC  
T-bet reverse: AGTAGGACATGGTGGGCCC  
T-bet probe: FAM-TGAAGCCTGCATTCTTGCCCTCTGC-BHQ 
The human real-time PCR primers/probe set for GAPDH (assay ID# 
Hs99999905_m1) was purchased from applied biosystems (Foster City, CA). 
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Cytokine detection 
Intracellular cytokine analysis of human Th cells stimulated with PMA and 
Ionomycin was performed as previously detailed (60). Cells were stained with the 
following antibodies against human cytokines: APC-conjugated anti-IFNγ and PE-
conjugated anti-IL-4 (Pharmingen). For detection of secreted cytokines, T cells 
were stimulated via antibody cross-linking for 18 hours. Supernatants were 
assayed using a cytometric bead array (CBA) according to the manufacturer’s 
instructions (BD Biosciences) (154), and analyzed using CBA 6-bead analysis 
software (BD Biosciences).  
 
Results  
 
Development of a lentiviral RNAi vector and selection for active T-bet shRNAs 
 
Gene-specific silencing by RNAi is an important, evolutionarily conserved 
mechanism of regulating gene expression and also provides a powerful genetic 
tool that can be utilized to identify and functionally characterize genes involved in 
a host of biological processes (201, 202). To date, however, wide spread usage 
of RNAi in mammalian cells has been relatively limited due to the lack of siRNA 
amplification and systemic spread that is seen in nematodes, drosophila and 
plants (198, 199). We bypassed the inherently transient nature of siRNA 
expression in mammalian cells by developing a lentiviral-based transduction 
system that confers stable siRNA expression. The salient features of the newly 
generated HIV-derived lentiviral vector used to express siRNA in human Th cells 
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(siLENT) include: 1) the vector is genetically modified as to be replication-
defective, 2) does not express any HIV accessory genes, enzymes or structural 
components, 3) contains the human U6 promoter upstream of shRNA 
oligonucleotides that activates the cellular RNAi machinery, and 4) carries a 
marker gene expression cassette (GFP) that is independently expressed off of 
the human ubiquitin C promoter, allowing for the identification and isolation of 
transduced cells via flow cytometry (Fig. 3-1). 
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Figure 3-1: Schematic diagram of lentiviral RNAi vector (siLENT). 
The HIV-derived vector (siLENT) developed for stable expression of siRNA in 
primary human Th cells is genetically modified as noted in the text. Importantly, 
the vector’s 5’ LTR is self-inactivating as to maintain transcriptional control of the 
shRNA oligo by the U6 promoter. 
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In order to further elucidate the role of T-bet in human Th cell 
differentiation we sought to generate and functionally validate T-bet-specific 
shRNAs. To this end, cDNA encoding the T-bet ORF was cloned into a reporter 
vector 3’ of firefly luciferase (Fluc) containing a stop codon between Fluc and T-
bet mRNA. Thus, chimeric mRNA molecules containing T-bet-tagged Fluc are 
produced (Fig. 3-2A) and T-bet-specific siRNA activity can be assessed upon 
triple-transfections of HEK-293T cells with the chimeric Fluc reporter vector, a 
control reporter vector (Renilla luciferase (Rluc) alone) and vectors containing the 
human U6 promoter driving expression of candidate T-bet shRNAs (Fig. 3-2B). 
Indeed, three of the 12 candidate shRNA oligos demonstrated strong T-bet-
specific siRNA activity as measured by the targeted down-regulation of the Fluc-
T-bet chimeric mRNA by approximately 80% without significantly altering 
expression of Rluc (Fig. 3-2C). Taken together, these findings demonstrate the 
generation and functional activity of T-bet shRNAs that potently and specifically 
inhibits T-bet mRNA expression. 
 
 
siRNA-mediated stifling of T-bet expression in developing Th1 cells inhibits 
acquisition of effector functions 
T-bet is a master transcription factor that orchestrates TN cell differentiation to 
Th1 effector cells (80, 81, 95, 122). In order to functionally validate the efficacy of 
T-bet-specific shRNAs in primary human Th cells we cloned a T-bet shRNA oligo 
(#2-Fig. 3-2C) into the siLENT vector and, as a proof of principle, first asked if 
expression of T-bet shRNAs inhibits human Th1 differentiation. 
67 
  
 
Figure 3-2: Development of and selection for T-bet siRNA.  
(A) Screening for active T-bet shRNAs were performed by triple transfection of 
HEK-293T cells with a Fluc reporter containing the T-bet mRNA sequence, a 
control Rluc vector and vectors expressing T-bet shRNA oligos. SiRNA activity 
was scored by specific down-regulation of Fluc signal, without perturbing Rluc. 
(B) The Fluc reporter vector using in the T-bet shRNA screening reactions was 
generated by cloning the mRNA sequence of human T-bet down-stream of Fluc, 
separated by a stop codon as to generate chimeric Fluc-T-bet mRNA molecules. 
(C) Screening reaction of 12 candidate T-bet shRNA oligos logically design using 
available algorithms. Fluc activity in each sample was normalized for Rluc 
activity. The positive control used is a Fluc-specific shRNA and the negative 
control is an irrelevantly designed shRNA that doesn’t affect T-bet expression. 
These screens were performed in triplicate reactions. 
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For these experiments TN cells purified from PBMC of healthy adult donors 
were TCR-activated via cross-linking antibodies under either non-polarizing (Th0) 
or Th1 polarizing cytokine conditions (see methods). TN cells driven to Th1 
differentiation were left uninfected, or were infected with lentiviruses containing 
either control (siLENT.control_shRNA) or T-bet-specific shRNA (siLENT.T-
bet_shRNA) at the time of activation. Transduced Th cells were expanded for 8-
10 days and T-bet expression was assessed via quantitative real-time PCR. T-
bet transcript levels were reduced nearly 5-fold in Th1 cells expressing siLENT.T-
bet_shRNA as compared to those expressing control shRNA (Fig. 3-3A), 
confirming our previous screening data where ~80% reduction was seen in T-bet 
mRNA levels (Fig. 3-2C). We next determined cytokine production and 
chemokine receptor expression in the transduced Th cells. As expected, TN cells 
activated under Th1 polarizing conditions produced more IFNγ and expressed 
higher levels of the Th1 chemokine receptor CXCR3 than non-polarized Th0 cells 
(Fig. 3-3B). Importantly, the observed siRNA-mediated inhibition of T-bet 
expression levels in T cells programmed to the Th1 lineage was in parallel with 
reduced IFNγ production and less cell-surface expression of CXCR3 (Fig. 3-3B). 
Additionally, expression of siLENT.T-bet_shRNA enhanced the secretion of Th2 
cytokines (IL-4, IL-5 and IL-10) and expression of the Th2 chemokine receptor 
CCR4 compared to both genetically unmodified Th1 cells and those expressing 
control shRNA (Fig. 3-3B, 3-3C). These key findings demonstrate that siRNA-
mediated silencing of T-bet expression in primary human TN cells inhibits their 
differentiation into Th1 effector cells. 
69 
 
 
Figure 3-3: T-bet siRNA inhibits TN cell differentiation to Th1 effector cells. 
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Figure 3-3 continued. 
(A) TN cells purified from healthy adult donors were activated under Th1 
polarizing cytokine conditions and transduced to express control or T-bet shRNA. 
Activated and transduced cells were expanded for 10 days in IL-2-supplemented 
media and FACS-sorted based on marker GFP expression to obtain pure 
populations. Sorted cells were then re-stimulated for 18 hours via α-CD3/α-CD28 
stimulation, lysed and T-bet mRNA expression was determined via quantitative 
real-time PCR. (B) TN cells were activated under either non-polarizing (Th0) or 
Th1 polarizing conditions. Those polarized to Th1 differentiation were 
simultaneously transduced with siLENT.control_shRNA, siLENT.T-bet_shRNA or 
left untransduced. All cells were expanded as in (A) for 8-10 days and unsorted 
cell populations were either re-stimulated with PMA/Ionomycin and probed for 
intracellular cytokine production or analyzed for cell-surface expression of Th1- 
and Th2-associated chemokines receptors as indicated. (C) Activated and 
transduced developing Th1 cells as in (B) were expanded for 8-10 days as 
above, sorted for marker GFP gene expression, re-stimulated for 18 hours via α-
CD3/α-CD28 stimulation and Th2 cytokine secretion was determined by CBA 
and FACS analysis. These data represent two sets of experiments using cells 
from individual adult donors. 
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T-bet expression in lineage-committed Th1 cells is dispensable for the 
maintenance of IFNγ production 
We have observed that repressing T-bet expression in TN cell programmed to 
differentiate into Th1 cells inhibits the acquisition of Th1 effector function and 
lymphoid trafficking potentials. However, the role of T-bet in maintaining Th1 
effector function upon lineage-commitment remains poorly elucidated. Therefore, 
we next determined if siRNA-mediated T-bet silencing affects the IFNγ-producing 
potential of Th1 effector cells. 
 For these experiments, Th1 cells were generated in vitro from TN cells as 
detailed above and were either left unmodified, or transduced with 
siLENT.control_shRNA or siLENT.T-bet_shRNA subsequent to lineage-
commitment. To account for the half-life of previously expressed T-bet protein 
within the cells and the fact that lentiviral-delivery of transgenes takes 
approximately 36-48 hours for high-level expression to ensue, transduced Th1 
cells were maintained in culture for 5 days prior to harvesting and intracellular 
cytokine analyses. Th1 cells expressing siLENT.T-bet_shRNA maintained high-
level, polarized IFNγ production that was indistinguishable from that of 
siLENT.control_shRNA-expressing cells and those Th1 cells left untransduced 
(Fig. 3-4). These data indicate that T-bet expression in lineage-committed Th1 
cells is dispensable for IFNγ production.  
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Figure 3-4: T-bet-independent maintenance of IFNγ  production in lineage-
committed Th1 cells. 
Adult blood human Th1 effector cells were generated via TCR-activation as in 
Figure 3-3 legend. 12 days post initial activation, differentiated Th1 cells were 
transduced with siLENT.control_shRNA or siLENT.T-bet_shRNA or left 
untransduced. To allow for siRNA synthesis and T-bet protein and transcript half-
life, cells were harvested 5 days post transduction and re-stimulated with 
PMA/Ionomycin to determine intracellular production of IL-4 and IFNγ. These 
data represent two independent experiments using cells from different donors. 
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Discussion 
 
Here we adapt a lentiviral-based gene delivery strategy to stably express T-bet 
siRNA in primary human Th cells. We demonstrate that T-bet expression is 
required for the differentiation of primary human TN cells to the Th1 effector 
subset but is expendable in maintaining high-level IFNγ production following 
lineage-commitment. These findings further elucidate the role of T-bet in the 
regulation of Th1 differentiation and regulation of effector function and also sheds 
new light into the complex molecular regulation of IFNγ within human Th cells.  
The production and regulation of IFNγ by Th cells is of critical importance 
to the activation of both innate and adaptive immunity against intracellular 
pathogens. Genetic deficiencies leading to weak IFNγ production by Th cells can 
lead to heightened susceptibility to acute and chronic intracellular parasitism in 
animal models (203-205), whereas dysregulated production of the cytokine can 
be pathogenic and is associated with severe auto-immune disorders (206, 207). 
Interestingly, T-bet knockout studies clearly suggest that the regulation of IFNγ is 
cell-type dependent. Th cells and innate NK cells lacking T-bet display severe 
impairment in IFNγ production, whereas CTLs do not require T-bet expression for 
high-level IFNγ production, suggesting both T-bet-dependent and independent 
IFNγ regulatory mechanisms may physiologically occur during immune activation 
(99). Yet whether impaired IFNγ production in Th cells lacking T-bet is due to a 
perturbation in Th1 effector cell development, or is the result of diminished IFNγ 
production by Th1 effector and memory T cells remains unresolved (98, 99). Our 
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results favor a model of bi-phasic model of IFNγ regulation during human Th cell 
differentiation wherein optimal acquisition of polarized, high-level IFNγ production 
in recently programmed Th1 cells is dependent upon T-bet expression. In 
contrast, our findings imply that lineage-committed Th1 effector cells can 
maintain high-level IFNγ-producing potential in a T-bet-independent fashion, 
analogous to CTLs. 
The T-bet independent IFNγ-production displayed by CTLs has prompted 
further investigation into the regulation of IFNγ in the absence of T-bet. Recently, 
a paralog of T-bet, called eomesodermin (eomes), was identified that is 
specifically induced upon activation of naïve CD8+ T cells and is sufficient to 
program their differentiation to IFNγ-producing CTLs, even in the absence of T-
bet (174). Indeed, ectopic expression of eomes in T-bet-deficient Th cells can 
also rescue Th1 differentiation and promote high-level IFNγ production upon 
antigen re-stimulation (174). Moreover, eomes+/- CTLs displayed significant 
impairment in both eomes expression and IFNγ production (174). However, while 
the identification of eomes provides novel insight into T-bet-independent 
mechanisms of IFNγ regulation, it is not expressed in Th cells, and thus cannot 
account for IFNγ maintenance in the absence of T-bet in this study. 
Another transcription factor, H2 O-like homeobox protein 1 (Hlx1), has 
been recently characterized to regulate IFNγ expression (163). Hlx1 is expressed 
in Th cells and appears to be important for stabilizing Th1 effector function and 
IFNγ expression. Hlx1 is induced in TN cells during Th1 development, and 
subsequently acts in concert with T-bet to potentiate IFNγ expression (163). 
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Extensive demethylation of the IFNγ locus ensues only after T-bet/Hlx1-co-
ordinated IFNγ expression, and thus Hlx1 may confer the stable T-bet-
independent IFNγ production displayed by Th1 effector T cells observed in the 
present study (163). Alternatively, as the siRNA-mediated silencing of T-bet 
observed is not 100%, it is also possible that lineage-committed Th1 effector 
cells require less T-bet to maintain high-level IFNγ production, analogous to the 
manner in which effector and memory Th cells are more sensitive to antigenic re-
stimulation (38, 155). 
In summary, through the development and expression of T-bet shRNA in 
primary human Th cells we show that T-bet is an obligate transcription factor 
during Th1 cell development that confers optimal acquisition of effector function 
and lymphoid trafficking tendencies. Upon lineage-commitment, however, T-bet 
expression appears to be dispensable for maintaining polarized IFNγ production. 
These findings provide novel insight into the role of T-bet in the regulation of Th1 
cell development and function and uncover a previously unappreciated 
mechanism of IFNγ regulation in Th cells. Moreover, the feasibility of expressing 
siRNA in primary human Th cells can be utilized to rapidly identify and functional 
characterize genes involved in T cell differentiation. 
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CHAPTER IV 
 
THE TRANSCRIPTION FACTOR GATA-1 POTENTLY REPRESSES THE 
EXPRESSION OF THE HIV-1 CO-RECEPTOR CCR5 IN HUMAN T CELLS AND 
DENDRITIC CELLS 
 
 
Abstract 
 
The major transmissible HIV-1 strains require expression of the chemokine 
receptor CCR5 for entry into CD4+ cells. The molecular mechanisms regulating 
CCR5 expression in the primary targets of HIV-1, human T cells, is poorly 
understood. Because the CCR5 promoter contains DNA-binding sites for GATA 
transcription factors, we investigated whether GATA transcription factors can 
regulate CCR5 expression. We show that expression of GATA-1 in primary 
human T cells, but not GATA-3, potently inhibits CCR5 expression, rendering 
cells refractory to infection by CCR5-tropic HIV-1. GATA-1 expression in other 
HIV-1 target cells, notably iNKT cells and dendritic cells, also suppresses CCR5 
expression. Mechanistically, GATA-1 inhibits CCR5 promoter activity and gene 
expression in human T cells, suggesting direct transcriptional repression. Despite 
the differential inhibition of CCR5 and other Th1-associated effector molecules 
(CXCR3 and IFNγ) exhibited by these GATA factors, we show that GATA-1 can 
functionally replace GATA-3 in programming Th2 gene expression. These 
findings indicate the DNA-binding domain shared between GATA-1 and GATA-3 
is sufficient to program Th2 cell differentiation but not for CCR5 repression. 
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These results lend novel insight into CCR5 gene regulation and T cell 
differentiation, which together can profoundly influence HIV-1 transmission and 
disease progression. 
 
Introduction 
 
CC chemokine receptor 5 (CCR5) is a receptor for β-chemokines that regulate 
the migration of leukocytes into inflamed peripheral tissues (208). CCR5 also 
serves as the primary co-receptor on CD4+ cells for viral entry of macrophage-
tropic strains of HIV-1, HIV-2 and SIV (126-128).  As such, β-chemokines 
secreted by cytolytic T cells or bioactive small molecule inhibitors that compete 
with HIV-1 gp120 for CCR5 binding and facilitate receptor internalization inhibit 
HIV-1 infection and replication (209-211). Moreover, individuals carrying a 
naturally occurring homozygous 32bp-deletion within the CCR5 ORF (CCR5Δ32) 
that precludes cell-surface expression, display almost complete resistance to 
HIV-1 transmission, infection and progression to AIDS (212-217). More recent 
reports have demonstrated that inhibition of CCR5 expression via intracellular 
immobilization (218) or siRNA (219) also renders T cells resistant to R5-tropic 
HIV-1 infection. Together these findings corroborate the pivotal role of CCR5 
expression during HIV-1 infection and highlight the importance of understanding 
how it is regulated.  
CCR5 is expressed within the immune system by CD4+ effector or 
memory T helper (Th) cells, invariant natural killer T (iNKT) cells, macrophages, 
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immature dendritic cells (DCs) and in bone marrow precursor cells during 
hematopoiesis (208, 220). While CCR5 expression in most cell types is uniform, 
its expression in human Th cells is highly variable and tightly linked to the type of 
effector function acquired during naïve T (TN) cell differentiation to effector and 
memory subsets. More specifically, CCR5 is prominently expressed on IFNγ-
secreting Th1 cells as compared to IL-4-producing Th2 cells (38, 88, 221). In 
addition to the differential expression of CCR5, Th1 cells also prominently 
express CXCR3 (88-90), whereas Th2 cells preferentially express CCR4 (88, 91) 
and the prostaglandin D2 (PGD2) receptor  (CRTH2) (60, 92, 93). Unique 
chemotactic receptor expression profiles on Th1 and Th2 cells, including CCR5, 
are critical for regulating their migratory propensities to sites of inflammation and 
may also determine cell susceptibility to HIV-1 infection.  
Promoter analyses of CCR5 have identified putative DNA binding sites for 
several transcription factors including members of the GATA family (129, 130, 
222). Moreover, a previous report has shown that GATA transcription factors can 
bind to CCR5 promoter elements and that GATA-1 expression in a T-lymphoid 
cell line trans-activates CCR5 expression (223). However, the potential 
regulation of CCR5 gene expression by GATA transcription factors within any 
physiologic cellular targets of HIV-1 has not been determined.  
Structurally, GATA transcription factors are comprised of either one or two 
centralized C4-type zinc-finger motifs that mediate DNA binding and protein-
protein interactions (110, 113, 224-227). Based on tissue expression profiles and 
the degree of sequence conservation within the zinc-finger domain of GATA 
79 
family members, GATA-1, GATA-2 and GATA-3 are most closely related, all of 
whom serve as key regulators of hematopoiesis in mammals (101, 138, 220, 
228-231). These GATA family members share significant sequence similarity 
within the zinc-finger domain, thus displaying similar DNA binding preferences for 
the consensus DNA element (A/T)GATA(A/G) (110-112, 232). However, 
homology in amino- and carboxy-terminal regions of GATA-1, -2, and –3 located 
outside the zinc-fingers is minimal.  
GATA-3 is a master regulator of TN cell differentiation into Th2 effector 
cells that predominantly produce the cytokines IL-4, IL-5 but not IFNγ and 
express the chemotactic receptors CCR4 and CRTH2 25,(79, 81, 103, 104, 157, 
233, 234). Indeed, expression of GATA-3 enhances Th2 cytokine production, 
decreases IFNγ secretion and promotes chromatin remodeling of the IL-4 locus 
(105-107).  On the other hand, GATA-1 is expressed in HSCs, erythroblasts, 
megakaryocytes, eosinophils and mast cells, serving to regulate 
megakaryopoiesis and erythropoiesis in mice and humans (220) (235-238). Mice 
lacking GATA-1 display severe hematopoietic dysfunction and do not survive 
gestation due to lethal anemia (239). In humans, mutations that interfere with 
GATA-1 expression or function result in lethal anemic disorders or hematopoietic 
cancers (240-242). Interestingly, studies using GATA-1-deficient embryonic stem 
cells or knock-out mice demonstrate that GATA-3 expression can rescue 
hematopoietic deficiencies and embryonic lethality in the place of GATA-1 (243-
245). However, adult animals that have GATA-3 substituted for GATA-1 generate 
reduced levels of improperly functioning platelets and erythrocytes suggesting 
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GATA-3 can not completely reconstitute GATA-1 function (244). Nevertheless, 
these findings suggest that the DNA binding zinc-finger domain of GATA-3, 
which is nearly 95% identical to that of GATA-1, is largely sufficient to direct 
hematopoiesis.  
Here we demonstrate that expression of GATA-1, but not GATA-3, 
potently inhibits CCR5 gene expression in primary human Th cell subsets, iNKT 
cells and DCs. As such, GATA-1-expressing human Th cells are resistant to 
infection by CCR5-tropic HIV-1. Similar to GATA-3, however, ectopic expression 
of GATA-1 in human naïve and memory Th cells programs Th2 cytokine and 
chemotactic receptor expression profiles. These findings identify GATA-1 as a 
potent transcriptional silencer of CCR5 expression and could have implications in 
regulating its expression in the context of HIV-1 infection. Moreover, our results 
highlight functional redundancies and divergences between heterologous GATA 
transcription factors, thus providing novel insight into the molecular regulation of 
Th cell differentiation by GATA-3. 
 
Materials and Methods 
 
Lentiviral vectors  
Construction and use of HIV-derived vectors (HDV) that contain bicistronic 
marker genes have been previously described (152). HDV bicistronically 
expressing GATA-3 and a marker gene (murine CD24 or GFP) has also been 
described (60). To generate HDV expressing GATA-1, murine GATA-1 was sub-
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cloned into the PmeI site of the HDV vector and confirmed by sequencing of the 
insert regions. Murine and human GATA-1 share 90% and 100% sequence 
identity within the open reading frame and zinc finger domains, respectively.  
 
Purification of T cell subsets 
PBMCs were isolated from neonatal placental cord blood or from adult blood by 
Ficoll (Pharmacia) density centrifugation. Resting CD4+ Th cells were purified as 
previously described using CD4-Dynabeads (60, 152) and were 99.5% 
CD4+CD3+ as determined by FACS analysis. Primary Th cells transduced with 
HDV express the reporter protein mCD24 on the cell surface and were enriched 
for by sorting for mCD24+ cells as described (60). In some experiments purified 
CD4+ T cells were further subdivided into central (CD45RO+CCR7+) and effector 
(CD45RO+CCR7-) memory and naïve (CD45RO-CCR7+) T cells from adult blood, 
using magnetic bead and flow cytometry (FACSAria) sorting as previously 
described (60). Human NKT cells were isolated from adult blood PBMC as 
previously described (246). 
 
CD34+ hematopoietic stem cell isolation, culture and DC differentiation 
Human CD34+ HSCs were isolated from neonatal umbilical cord blood. Briefly, 
total mononuclear cells recovered from cord blood (see purification of resting 
human T cells section) were positively sorted for stem cells via automated 
magnetic sorting using anti-CD34 antibodies directly conjugated to MACS beads 
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(Miltenyi). Purified stem cells were cultured in serum free media (Stem Cell 
technologies, serum free expansion media (SFEM) – catalogue #: 09600) 
supplemented with stem cell factor (SCF, 50 ng/ml), FMS-related tyrosine kinase 
3 ligand (Flt3L, 100 ng/ml), IL-3 (20 ng/ml), thrombopoietin (200 ng/ml) (all from 
R&D systems) and penicillin/streptomycin (Cellgro) for the first 3 days following 
purification. HSCs were subsequently expanded for an additional 6-8 days in 
serum free media containing SCF. Stem cells were then harvested and either 
kept in SCF-containing serum free media to maintain pluripotency or washed and 
cultured in DC-differentiating media: RPMI plus 10% FCS supplemented with 
human IL-4 (50 ng/ml) and GM-CSF (20 ng/ml) (R&D systems). DC 
differentiation from HSCs was confirmed via staining for CCR5 expression along 
with anti-CD1a (BD biosciences) or anti-CD1c (Miltenyi) antibodies and FACS 
analysis 4-6 days post differentiation.  
 
 
T cell activation and differentiation  
Activation and differentiation of purified human CD4+ Th cells was accomplished 
via TCR stimulation using anti-CD3 (OKT3, ATCC) and anti-CD28 (BD 
Biosciences) antibodies in the presence or absence of polarizing cytokines as 
described (60). Briefly, 96 well plates were coated with 10 µg/ml goat-anti-mouse 
IgG (Caltag) for one hour at 37˚C. Wells were washed twice with PBS and coated 
with 0.5 µg/ml anti-CD3 for an additional hour at 37˚C. After washing to remove 
unbound CD3 antibodies, T cells were added to antibody-coated wells with 
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soluble anti-CD28 (1 µg/ml) in the presence of Th1 or Th2 polarizing cytokine 
conditions as previously described (60). Cells were removed from activation 
signals after 48 hours and expanded in recombinant human IL-2 (Chiron, 200 
U/ml) supplemented media. iNKT cells were purified cells, activated and 
expanded as previously described (246). The culture media used in all 
experiments was RPMI supplemented with 10% fetal calf serum as described 
previously (152).  
 
Virus production and infections  
VSV-G pseudotyped, replication incompetent HIV-derived viruses (HDV) were 
generated as previously described (152). For HDV, HDV.GATA-3 or HDV.GATA-
1 transduction experiments, TCR-activated Th cells or NKT cells were infected in 
flat-bottom 96- or 24-well plates at a multiplicity of infection (MOI) of 3-8. Stem 
cell-derived DCs were infected after 4 days in DC differentiating media at 5 MOI. 
For some experiments, cells inoculated with virus were centrifuged for 1 h at 
2,000 rpm to enhance infections as described (153). Replication-competent HIV-
1 infections of purified HDV-, HDV.GATA-3- or HDV.GATA-1-expressing Th cells, 
were conducted by inoculating T cells with various MOIs of CCR5-tropic 
replication-competent strain of HIV (R5.HIV) or with VSV-G-pseudotyped, 
replication-incompetent HIV (VSV-G.HIV). The latter two viruses were 
engineered to express GFP in the place of the nef gene. HIV-1 infection of Th 
cells was monitored by FACS analysis of GFP expression and viral replication 
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was determined by quantifying the HIV-1 core protein p24 in culture supernatants 
by ELISA.  
 
Antibodies and FACS Analysis   
Cells were stained with the relevant antibodies and analyzed using a flow 
cytometer (FACSCalibur®) as previously described (60) Analysis was performed 
using FlowJo software (Tree Star). The following anti-human antibodies were 
used for staining: CD3, CD4, CD45RO, CD45RA, CCR4, CCR5, CXCR3, CCR4, 
CD1a and CD1c (all from BD Biosciences), CCR7 (R&D sciences), anti-Vβ11 
(Coulter) and a murine antibody against CD24 (HSA)(Pharmingen). The CRTH2 
antibody used for these experiments has been described previously (92) 
 
Real time PCR  
Total RNA and cDNA synthesis from primary cells was performed as described 
(247). The cDNA was used to perform real-time PCR to determine expression 
levels of GATA-3, GATA-1 and CCR5, with GAPDH levels being concurrently 
assessed as to normalize samples for differences in RNA content. Real-time 
PCR was conducted using the TaqMan universal PCR Master Mix (Roche) in a 
Model 7900 ABI Sequence Detection System. The sequences of the primers and 
probes are as follows:   
GATA-3 forward: GGACGAGAAAGAGTGCCTC 
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GATA-3 reverse: TGGGACGACTCCAGCTTCA 
GATA-3 probe: FAM-AGGTGCCCCTGCCCGACAGC-BHQ 
Human real-time PCR primers/probe sets for CCR5 (assay ID# 
Hs00152917_m1), GAPDH (assay ID# Hs99999905_m1) and GATA-1 (assay 
ID# Hs00231112_m1) were purchased from Applied Biosystems (Foster City, 
CA). 
 
CCR5 promoter analysis in T cells 
To study the regulation of CCR5 promoter activity, TCR-activated primary human 
Th cells expressing HDV, HDV.GATA-3 or HDV.GATA-1 were re-stimulated via 
anti-CD3 and anti-CD28 antibodies for 24 hours as described above. 1-2 x 106 
cells were then harvested, washed twice with PBS and resuspended in 160µl 
human T cell nucleofection buffer (Amaxa). Cells were transfected with 2 µg of 
either the promoterless pGL3-Basic vector (Promega) or a vector that contains a 
CCR5 promoter construct that spans both promoters 1 and 2. The design of this 
CCR5 promoter construct were described previously and are shown in Fig. 5 
(130). The CCR5 promoter construct was cloned upstream of the luciferase gene 
in this vector.  0.3 µg of a renilla gene-containing vector, (pHRL-CMV vector-
Promega) DNA was added to cells to normalize for transfection efficiency. The 
cell/DNA mixtures were transfected via a nucleofection device (Amaxa) per 
manufacturers’ instructions. Following transfection, cells were immediately 
diluted into fresh IL-2-supplemented media and cultured for 18 hours. Cells were 
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subsequently lysed and both firefly and Renilla luciferase activities were 
determined using a Dual-Luciferase assay kit per recommendations of the 
manufacturer (Promega) and analyzed using a luminometer (Mediators PhL).  
 
Cytokine detection 
Intracellular cytokine analysis of human Th cells stimulated with PMA and 
ionomycin was performed as described previously (60). Cells were stained with 
antibodies for the following human cytokines: APC-conjugated anti-IFNγ, PE-
conjugated anti-IL-4, PE-conjugated anti-IL-13 and APC conjugated anti-IL-5 (all 
from Pharmingen). For detection of secreted cytokines, Th cells were stimulated 
via antibody cross-linking for 18 hours. Supernatants were assayed using a 
cytometric bead array (CBA) per manufacturer’s instructions (BD Biosciences) 
and analyzed using CBA 6-bead analysis software (BD Biosciences) using flow 
cytometry. 
 
Western blot analysis of GATA-3 and GATA-1 expression 
Western blot analyses on primary human Th cells transduced with either the 
control HDV, HDV.GATA-3, or HDV.GATA-1 was performed as described 
previously (60). Blots were performed first by probing with anti-GATA-3 (Santa 
Cruz, HG3-31) antibodies followed by HRP-conjugated anti-mouse IgG. Blots 
were developed using West Pico luminol/peroxide solutions (Bio-Rad) and 
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autoradiographed (Amersham). The membranes were stripped using a 
commercially available stripping solution (Bio-rad) for 5 min at 370C and 7 min at 
room temperature. Stripped membranes were re-probed with anti-GATA-1 
(Abcam) antibody followed by HRP-conjugated anti-rabbit antibody. To normalize 
for protein content, the membranes were stripped again and probed with anti-β-
actin (Santa Cruz, I-19) antibody followed by anti-mouse IgG-HRP. All HRP-
conjugated secondary antibodies were obtained from Jackson Laboratories. 
 
Results 
 
Expression of GATA-1 is down-regulated as human CD34+ stem cells 
differentiate into DCs and up-regulate CCR5. 
 
GATA transcription factors have been implicated in the regulation of CCR5 
expression. CCR5 promoter regions contain multiple DNA-binding sites for GATA 
transcription factors (129, 130) and expression of GATA-3 during Th cell 
differentiation promotes development of Th2 effector cells that express low levels 
of CCR5 (79, 88). However, ectopic expression of GATA-3 in CCR5 expressing T 
cells does not markedly reduce its expression (our unpublished data and Figure 
4-2). Therefore, we sought to determine if other GATA transcription factors may 
be capable of regulating CCR5 expression. As such, we chose to investigate the 
potential role of GATA-1 in CCR5 regulation. GATA-1 has previously been shown 
to bind to the CCR5 promoter and trans-activate CCR5 gene expression in a 
transformed T-lymphoid cell line (223). While, GATA-1 is not expressed on T 
cells, it is expressed in CD34+ hematopoietic stem cells (HSCs) (220) ,(248). 
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HSCs can differentiate into immature dendritic cells (DCs) that express robust 
levels of CCR5 (249) and are primary targets of initial HIV-1 infection upon viral 
transmission (250-252). We therefore asked if there was a relationship between 
GATA-1 and CCR5 expression during HSC differentiation into DCs.  
Primary human HSCs were isolated from neonatal umbilical cord blood 
and expanded in SCF-supplemented media for 8-10 days to pluripotency. Cell-
surface CCR5 and endogenous GATA-1 expression were assessed via flow 
cytometric and quantitative real-time PCR analyses, respectively (Fig. 4-1). 
HSCs were either maintained in SCF-supplemented media or were washed and 
cultured in DC-differentiating media. CCR5 and GATA-1 expression levels were 
evaluated throughout 6-day culture periods. Human HSCs express high levels of 
GATA-1 while only minimally expressing CCR5 (Fig. 4-1). Intriguingly, as HSCs 
were driven to differentiated into DCs, GATA-1 expression was decreased while 
CCR5 expression levels was greatly increased (Fig. 4-1). These findings suggest 
that GATA-1 may physiologically repress CCR5 gene expression in bone marrow 
precursor cells that are potential targets of HIV-1 infection.  
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Figure 4-1. Endogenous GATA-1 expression is inversely related with CCR5 
expression in human CD34+ hematopoietic stem cells upon DC 
differentiation.  
Purified and expanded primary human HSCs were cultured in stem cell media or 
DC differentiating media (see methods) for 6 days and (A) cell surface CCR5 
expression was assessed every 3 days via flow cytometry or (B) endogenous 
GATA-1 mRNA levels were determined via quantitative real-time PCR. These 
data represent 2 experiments performed using stem cells isolated from 
independent umbilical cord blood samples. 
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Expression of GATA-1 in primary cellular targets of HIV potently reduces CCR5 
expression 
 
In order to directly test if GATA-1 can regulate CCR5 expression we ectopically 
expressed either GATA-1 or GATA-3 in either stem cell-derived dendritic cells or 
T cells. For these experiments, we first generated stem cell-derived DCs as 
described above and transduced with lentiviral vectors encoding GATA-1 
(HDV.GATA-1) or GATA-3 (HDV.GATA-3). To express GATA transcription 
factors in T cells subsets, CD4+ T cells were first isolated from healthy 
individuals. These cells were further fractionated into naïve (TN - CD45RO- 
CCR7+), central memory (TCM - CD45RO+ CCR7+) and effector memory (TEM - 
CD45RO+ CCR7-) subsets, since these cells differ in their CCR5 expression and 
effector functions (44). In addition, iNKT cells, which have been shown to 
express high levels of CCR5 and be highly susceptible to HIV-1 infection (246, 
253-255) were also prepared as previously described (246). Once isolated, all T 
cell subsets were TCR-activated and simultaneously transduced to express HDV, 
HDV GATA-3 or HDV.GATA-1 that bicistronically expresses a reporter gene, 
mCD24, which is expressed on the cell surface of transduced cells. Transduced 
T cells were expanded for 8-10 days in IL-2-supplemented media and CCR5 
expression on mCD24+ T cells and DCs was determined via flow cytometry.  
Ectopic expression of GATA-1 or GATA-3 in transduced DCs and T cells 
was confirmed at the mRNA level with real-time PCR analysis (data not shown) 
and protein expression levels were determined by western blot analyses on 
primary human T cells transduced with HDV.GATA-1, HDV.GATA-3 or the 
control HDV (Fig. 4-2). Expression of GATA-1, but not GATA-3 profoundly 
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suppressed CCR5 expression in both dendritic cells (Fig. 4-3A) and effector T 
cell subsets (Fig. 4-3B). Furthermore, GATA-1-mediated CCR5 repression was 
stable as it was maintained 7-12 days post transduction (data not shown).  On 
the other hand, GATA-3-expressing cells only displayed modest reductions in 
CCR5 levels (Fig. 4-3). Together these key findings demonstrate GATA-1 is a 
potent repressor of CCR5 expression in DCs, conventional Th cell subsets and 
iNKT cells, all of which are targets of HIV-1 infection in vivo. Moreover, the 
differential regulation of CCR5 by GATA-1 and GATA-3 strongly suggest that the 
highly conserved zinc-finger domain is not sufficient to suppress CCR5 
expression. 
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Figure 4-2. Expression of GATA-3 and GATA-1 in transduced cells.  
Purified human Th cells were activated and transduced with either HDV, 
HDV.GATA-3 or HDV.GATA-1 viruses (see methods). Cells were expanded for 8 
days in IL-2-suplemented media and magnetically sorted for mCD24 expression. 
Sorted cells were lysed and western blot analyses were performed for GATA-3 
(upper panel), GATA-1 (middle panel) and β-actin (lower panel) expression using 
specific antibodies. The membranes were stripped following each blot and re-
probed in the order indicated above. These data are representative of two 
separate western blot experiments using transduced cells obtained from different 
donors. 
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Figure 4-3. Ectopic expression of GATA-1 inhibits CCR5 expression in 
human target cells of HIV-1. 
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Figure 4-3 continued. 
(A) Primary human HSCs were cultured in DC media for 4 days to drive 
differentiation (see methods). At day 4, DCs were transduced with HDV, 
HDV.GATA-1 or HDV.GATA-3 and cultured for an additional 4 days. CCR5 
expression on stem cell-derived DCs was determined via flow cytometric 
analyses by co-staining cells with anti-CCR5, a PE-conjugated anti-human CD1c 
antibody (Miltenyi Biotech) to monitor DC differentiation and anti-mCD24 
antibodies to resolve DCs expressing the lentiviral transgene. (B) Primary human 
conventional Th cell subsets (upper 3 panels) or iNKT cells (bottom panel) were 
TCR-activated and transduced to express GATA-1, GATA-3 or the control HDV 
(see methods). T cell subsets were all expanded in the presence of IL-2 and cell-
surface CCR5 expression was determined on unsorted populations of 
transduced cells and co-stained with anti-mCD24 antibodies as above. 
Additionally, CCR5 expression on iNKT cells were further stained with a FITC-
conjugated anti-human Vβ11 antibody (Coulter), to exclude any contaminating 
non-iNKT cells. These results are representative of at least 3 experiments 
performed on each cell type from unique adult or umbilical cord blood 
preparations. 
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GATA-1 expression in human T cells inhibits R5-tropic HIV-1 infection. 
 
CCR5 cell-surface expression levels closely correlates with susceptibility to HIV-
1 infection in vitro (256). In vivo, allelic or mutational variants of CCR5 that alter 
cell-surface expression of the chemokine receptor can influence the rate of HIV-1 
pathogenesis (213-217). In light of our finding that GATA-1 mediates potent 
CCR5 down-regulation in HIV-1 targets, we assessed if GATA-1-mediated down-
regulation of CCR5 renders Th cells less susceptible to HIV-1 infection. To test 
this, TCR-activated primary human Th cells were transduced to express GATA-1, 
GATA-3 or the control HDV and expanded for 7-8 days. The transduced cells 
were then purified by sorting for mCD24-expressing cells, and infected with either 
replication-competent HIV-1 that use CCR5 as a co-receptor (R5.HIV) or 
replication-defective HIV-1 pseudo-typed with the envelope glycoprotein of the 
vesicular stomatitis virus (VSV-G.HIV) that bypasses the CCR5 requirement for 
viral entry. HIV-1 infection and replication within Th cells were assessed over the 
course of nine-day cultures as described (246). Th cells expressing the control 
HDV and HDV.GATA-3 were readily susceptible to R5.HIV infection, thus virus 
replicated and spread efficiently within the culture (Fig. 4-4A). In contrast, GATA-
1-expressing Th cells displayed reduced initial R5.HIV infection and subsequent 
spread of infection and viral replication was markedly diminished in these 
cultures (Fig. 4-4A). GATA-1-expressing cells were, however, highly susceptible 
to infection with VSV-G.HIV (Fig. 4-4B), suggesting the limitation in R5.HIV 
infection of Th cell expressing GATA-1 is specifically due to reduced expression 
of CCR5 levels.  
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Figure 4-4. GATA-1-induced CCR5 down-regulation inhibits R5-tropic 
HIV-1 infection of human Th cells. 
Th cells expressing GATA-3 or GATA-1 were prepared as described in the 
figure 1 legend. mCD24+ cells were sorted and super-infected with either (A) 
replication-competent CCR5-tropic HIV-1 (R5.HIV) or with (B) replication-
incompetent VSV-G-pseudotyped HIV-1 (VSV-G.HIV) at MOI of 1. Cultures 
were maintained for 9 days and infected cells were analyzed every 3 days for 
GFP expression (left panel). Infections were normalized to the maximum 
infection of HDV-expressing T cells at day 9 (~8%). Culture supernatants 
were also collected at the indicated times post infection with R5.HIV and viral 
replication was quantified via p24 ELISA (right panel). These data are 
representative of three independent experiments performed using T cells 
isolated from individual donors. 
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Expression of GATA-1 in primary human T cells potently suppress CCR5 
promoter activity 
 
Because GATA-1-mediated CCR5 repression was remarkably similar across 
multiple cell types, we next asked how GATA-1 inhibits CCR5 cell-surface 
expression. We hypothesized that GATA-1 negatively regulates CCR5 gene 
expression. To test this possibility, we determined CCR5 mRNA levels by 
quantitative real-time PCR in human Th cells isolated from healthy donors. Th 
cells were TCR-activated via cross-linking antibody stimulation and transduced 
with HDV, HDV.GATA-3 or HDV.GATA-1. Cells were expanded and cell-surface 
CCR5 down-regulation in GATA-1-expressing Th cells was confirmed by flow 
cytometric analysis (Fig. 4-5A). Transduced cells were then sorted based on 
mCD24 expression and either left un-stimulated in IL-2 media or were re-
stimulated through the TCR for 18-24 hours. Cells were lysed and real-time PCR 
analysis of CCR5 mRNA levels was performed. GATA-1-expressing Th cells 
displayed approximately 10-fold less CCR5 transcript levels compared to those 
expressing the control HDV (Fig. 4-5B). By contrast, the reduction in CCR5 
mRNA was only 2-fold lower in GATA-3-expressing cells (Fig. 4-5B), findings that 
were concordant with our previous observations that GATA-3 was much less 
efficient compared to GATA-1 in reducing CCR5 cell surface expression level. 
 Because GATA-1-expressing cells had lower RNA and protein expression 
of CCR5, we next asked if this effect was, in part, mediated by repression of 
CCR5 promoter activity. To evaluate activity of the CCR5 promoter in primary 
human Th cells expressing GATA-1 or GATA-3, we generated and sorted cells 
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transduced with these transcription factors as described above. The cells were 
re-stimulated for 18-24 hours and transfected with either a construct containing 
the full-length CCR5 promoter 1 and 2 (Fig. 4-5C, upper panel) driving firefly 
luciferase expression or a promoterless firefly luciferase construct. Cells were 
harvested 24 hours post transfection and luciferase activity was analyzed. GATA-
1 expression in primary human Th cells significantly reduced CCR5 promoter 
strength compared to both control and GATA-3-expressing Th cells (Fig. 4-5C, 
lower panel), with promoter activity displaying levels similar to background. A 
slight decline in CCR5 promoter activity was observed in the cells expressing 
GATA-3 compared to those expressing the control HDV (Fig. 4-5C, lower panel), 
mirroring the modest inhibition of CCR5 message and cell-surface protein levels. 
These findings indicate that CCR5 promoter activity in primary human Th cells is 
potently silenced in the presence of GATA-1, whereas only a slight reduction is 
seen with GATA-3.  
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Figure 4-5. GATA-1 expression in primary human Th cells suppresses 
CCR5 promoter activity. 
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Figure 4-5 continued. 
(A) Total resting CD4+ T cells were TCR-activated and transduced with HDV, 
HDV.GATA-3 or HDV.GATA-1 as in the figure 1 legend. Transduced cells were 
expanded for 8-10 days and cell-surface expression of CCR5 was assessed on 
unsorted cells by staining with either isotype control (gray peaks) or anti-CCR5 
(white peaks) antibodies in conjunction with an anti-mCD24 antibody. The 
histograms are gated on the mCD24+ populations and the percent of CCR5 
positive T cells are displayed. The displayed histograms are representative of 6 
independent stainings performed on cells isolated from 6 different blood donors. 
(B) Total CD4+ human T cells expressing HDV, HDV.GATA-1 or HDV.GATA-3 as 
in the figure 5A were sorted based on mCD24 expression (see methods) and 
either left un-stimulated (resting) or re-stimulated via anti-CD3 and anti-CD28 
cross-linking for 18 hours (re-stimulated). Cells were lysed, cDNA was generated 
and quantitative real-time PCR was performed using gene-specific primers. Data 
was analyzed by normalizing CCR5 expression levels to GAPDH levels and are 
displayed as fold differences in relative expression. These data represent three 
independent real-time PCR reactions run from cDNA generated from separate 
sets of cells from different donors. (C) Top panel - Genomic organization of 
CCR5. Exons are represented as numbered white boxes, with exons signified by 
areas above numbered black boxes. +1 represents the start site of the open 
reading frame and every number is relative to it. Promoters 1 and 2 are as 
indicated, with GATA binding sites indicated and numbers represent the start of 
the binding sites. Bottom panel - Human Th cells positively sorted for mCD24 
expressing HDV, HDV.GATA-1 or HDV.GATA-3 were re-stimulated through the 
TCR as in the figure 1B legend. The cells were transfected with either a plasmid 
containing the full-length CCR5 promoter driving firefly luciferase expression or a 
promoterless-firefly luciferase plasmid. Cells were co-transfected with a CMV-
driven renilla luciferase expression plasmid (see methods). Transfected cells 
were lysed and luciferase expression was quantified. Firefly luciferase levels 
were normalized to renilla levels within samples and the data are displayed as 
relative fold induction of firefly luciferase as driven by CCR5 promoter over the 
promoterless control vector. These data represent three independent sets of 
transfections performed on cells from separate donors. 
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GATA-1 expression in naïve and memory Th cell subsets induces Th2 effector 
cytokine profiles. 
 
The above results demonstrated remarkably distinct regulation of CCR5 gene 
expression by GATA-1 and GATA-3. However, GATA-1 and GATA-3 contain a 
highly conserved zinc-finger domain and that they likely bind to very similar DNA 
sequences (110, 111). Moreover, previous studies have demonstrated that 
GATA-3 expression in GATA-1-deficient embryonic stem cells or knock-out mice 
can rescue hematopoietic deficiencies and embryonic lethality in the place of 
GATA-1 (243-245), suggesting a high degree of functional redundancy may exist 
between GATA-1 and GATA-3. Therefore, we sought to determine if the 
reciprocal was also true. We asked whether GATA-1 could redundantly program 
Th2 cytokine gene expression in human naïve and memory Th cell subsets 
similar to GATA-3 (60). 
 For these experiments, TN, TCM and TEM cells were isolated as before. 
These Th cell subsets were then TCR-activated and transduced with 
HDV.GATA-1, HDV.GATA-3 or the control HDV. The cells were expanded in IL-
2-supplemented media for 8-10 days and were probed for intracellular 
expression of Th1 and Th2 cytokines. Similar to GATA-3, ectopic expression of 
GATA-1 in both TCM and TEM subsets resulted in a marked up-regulation of IL-4 
and IL-13, and to a lesser extent IL-5, compared to memory T cells that only 
expressed HDV (Fig. 4-6). Interestingly, TCM and TEM cells ectopically expressing 
GATA-1 produced less IFNγ compared to either control- or GATA-3-expressing 
memory T cells (Fig. 4-6). Given the similar expression levels of GATA-1 and 
GATA-3 observed in transduced cells (Fig. 4-2), these data suggest the 
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quantitative differences in cytokine production are not due to differential 
expression of the transcription factors. Collectively, these findings indicate that 
expression of GATA-1 in primary human naïve and memory Th cells promotes 
the expression of Th2 cytokines and down-regulates IFNγ more effectively than 
GATA-3.   
 We further determined if GATA-1-directed Th2 programming was 
occurring indirectly, through the induction GATA-3 expression. Indeed, a 
previous report demonstrated that expression of heterologous GATA 
transcription factors in murine T cells activates GATA-3 expression, thereby 
promoting Th2 differentiation (257). However, in our studies we did not detect 
GATA-3 protein expression in human Th cells ectopically expressing GATA-1 
(Fig. 4-2 and data not shown). Quantitative real-time PCR analyses comparing 
GATA-3 expression levels in primary human Th cells expressing GATA-1 to Th1 
and Th2 cells corroborated these results. We found high-level GATA-3 mRNA 
expression was tightly restricted to Th2 cells and GATA-1-expressing cells did 
not display elevated GATA-3 levels compared to those expressing the control 
HDV (Fig. 4-7). Moreover, GATA-3 expression levels in cells expressing GATA-1 
mirrored those found in Th1 cells and were between 10- to 17-fold lower than 
those observed in Th2 cells (Fig. 4-7). The failure to detect expression of GATA-
3 in GATA-1-expressing cells strongly suggests that GATA-1 directly and 
redundantly programs Th cell cytokine gene expression similar to GATA-3. 
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Figure 4-6. Ectopic GATA-1 expression in human TN, TCM and TEM cells 
leads to Th2 cytokine profiles.  
CD45RO-RA+ naïve and CD45RO+RA- memory T cells were purified from adult 
blood PBMC of healthy donors via magnetic bead cell sorting (see methods) and 
were sorted by FACS for expression of CCR7 into TCM (CCR7+) and TEM (CCR7-) 
cells. The Th cell populations were activated for 48 hours through the TCR via 
antibody stimulation and infected with viruses containing either HDV, 
HDV.GATA-1, or HDV.GATA-3 at the time of TCR-activation as described in the 
materials and methods. After 8-10 days of expansion, intracellular expression of 
the cytokines IFNγ, IL-4, IL-5 or IL-13 were determined by flow cytometry (see 
methods). For these experiments transduced cells were left unsorted, but 
mCD24+ cells were identified and gated on by co-staining with an anti-mCD24 
antibody. These data are representative of three separate experiments using 
memory T cell subsets purified from different adult donors. 
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Figure 4-7. Expression of GATA-1 in human Th cells does not induce 
GATA-3 expression. 
Human TN cells purified from adult blood or neonatal umbilical cord blood were 
activated through the TCR in Th1 or Th2 cytokine conditions (see methods). 
Additionally, TN cells were also activated without polarizing cytokines and 
infected with viruses containing HDV or HDV.GATA-1 and all cells were 
expanded for 8-10 days in the presence of IL-2-supplemented media. 
Transduced cells were sorted for mCD24 expression and cells were then either 
left un-stimulated (resting) or re-stimulated with anti-CD3 and anti-CD28 
antibodies (re-stimulated) for 8 hours. Resting and re-stimulated T cells were 
harvested and GATA-3 expression was evaluated by quantitative real-time PCR. 
These data were analyzed by normalizing GATA-3 expression levels to GAPDH 
levels and are displayed as relative GATA-3 expression (fold differences). These 
data represent 3 experiments using TN cells from three independent adult or 
umbilical cord blood donors. 
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Expression of GATA-1 in primary human naïve and memory T cells reprograms 
chemotactic receptor expression patterns to a Th2 profile 
 
We found that expression of GATA-1 in human Th cells could functionally replace 
GATA-3 to program Th2 cytokine gene expression. However, given the distinct 
regulation of CCR5 observed between GATA-1 and GATA-3, we next determined 
if GATA-1 expression in human naïve and memory Th cells also influences the 
cell-surface expression of Th2-associated chemotactic receptors analogous to 
GATA-3 (60).  
 Human Th cell subsets were TCR-activated and transduced with 
HDV.GATA-1, HDV.GATA-3 or the control HDV and chemotactic receptor 
expression profiles were determined. Similar to GATA-3 expression in all three 
Th cell subsets, expression of GATA-1 was associated with induction of the Th2 
chemotactic receptors CCR4 and CRTH2 (Fig 4-8).  However, expression of 
GATA-3 in memory T cell subsets failed to suppress expression of the Th1-
biased chemokine receptor CXCR3, whereas GATA-1 expression reduced 
CXCR3 cell-surface expression in TCM and TEM cells (Fig. 4-8). These results 
provide further evidence that GATA-1 and GATA-3 can induce both Th2 effector 
function and cell migration patterns by influencing the expression of chemotactic 
receptors. However, the effects of GATA-3 and GATA-1 are not completely 
redundant as GATA-1 is a significantly more potent repressor of Th1 chemokine 
receptors and effector molecules relative to GATA-3 (Table 4-1). 
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Figure 4-8. Expression of GATA-1 in human TN, TCM and TEM cell subsets induces Th2- and potently inhibits Th1-
associated chemokine receptors. 
Human TN, TCM and TEM cells were purified, activated, and transduced with HDV alone, HDV.GATA-1, or HDV.GATA-3 
(see methods). Following expansion, unsorted cells were stained with antibodies against CXCR3, CCR5, CCR4, CRTH2 
or the appropriate isotype control in conjunction with an anti-mCD24 antibody to gate on transduced populations. The 
percent of cells positive for the appropriate chemokine receptor is shown, with the gray, tinted peak representing isotype 
control staining. Results are representative of one of three experiments using T cell subsets from distinct adult donors. 
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Table 4-1: GATA-1-mediated repression of Th1 effector molecules. 
 
 
 
*   Concentration of IFNγ (pg/ml) secreted 18 hours-post TCR stimulation as 
determined by CBA  
**  Mean fluorescent intensity (MFI) of CXCR3 cell surface expression as 
determined by FACS analysis 
*** Mean fluorescent intensity (MFI) of CCR5 cell surface expression as 
determined by FACS analysis 
+     Significantly lower than Th1-HDV (p=<.05) and Th1-HDV.GATA-3 (p=<.05) 
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Table 4-2: Summary of GATA-1 and GATA-3 effects on gene expression in T 
cells. 
 
Each + represents 20% change in T cell subsets expressing the indicated protein 
as monitored by flow cytometry compared to HDV-expressing T cells. 
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Discussion 
 
Despite its critical importance in the pathogenesis of HIV-1, there is a significant 
knowledge gap in our understanding of the molecular determinants that control 
CCR5 expression in the physiologic cellular targets of HIV-1. By concurrently 
comparing the effects of GATA-3 and GATA-1 on CCR5 expression, we 
demonstrate that these two TFs mediate markedly distinct regulatory effects on 
CCR5 expression, but also display overlapping functions in the regulation of Th1 
and Th2 gene expression during T cell differentiation (summarized in Table 4-2).   
Given that GATA-3 is highly expressed on Th2 cells, and that these cells 
display lower levels of CCR5, we had hypothesized that ectopic expression of 
GATA-3 would suppress CCR5 expression levels. However, this was not the 
case, and by contrast, GATA-1 potently repressed CCR5 expression at both the 
protein and transcript levels in primary human T cell subsets and DCs. These 
effects are, in part, mediated by the inhibition of CCR5 transcription, and support 
the notion that GATA TF binding to their cognate cis-elements within the CCR5 
promoter is functional (Fig. 4C and refs (129, 130)). Interestingly, GATA-1 was 
previously shown to trans-activate CCR5 promoter activity in a transformed T-
lymphoid cell line (223). However, our results clearly demonstrate that GATA-1 is 
a potent repressor of CCR5 expression in primary human T cells and dendritic 
cells. This discrepancy in CCR5 regulation by GATA-1 in primary versus 
transformed cell lines may reflect unique combinations or levels of TFs present 
within constitutively proliferating cells that do not faithfully mimic those in 
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physiological primary cells. Substantiating this possibility, we recently found that 
the CCR5 promoter 2 (258) is highly active in primary cells compared to cell lines 
that serve as surrogates for T cells (e.g. Jurkat) (Mummidi et al, manuscript in 
preparation). Moreover, the differential effects of GATA-1 in T cell lines and 
primary T cells may also be attributed to other differences in these cell types, 
such as cell-type specific differences in the epigenetic architecture of the CCR5 
locus.  
The precise mechanism by which GATA-1 represses CCR5 gene 
transcription is not yet clear, and two possible mechanisms can be envisaged. 
First, GATA-1 might influence CCR5 transcription independently or, as reported 
previously in other gene systems, in concert with other TFs that bind to cis-
elements within the CCR5 promoter (129, 130, 236, 259). Second, GATA-1 may 
epigenetically remodel the CCR5 promoter. This possibility is based on the 
finding that GATA-1-responsive loci are epigenetically modified during 
hematopoiesis (220). If, in fact, GATA-1 restructures chromatin within the CCR5 
locus, this could cause a transcriptionally silent imprint in HSCs during 
hematopoiesis that may be maintained in developing T cells. Indeed, TN cells that 
develop in the thymus and are maintained in the periphery do not express CCR5 
and require extracellular activation signals to induce its expression (208). 
Whether GATA-1 can regulate an epigenetically silent imprint at the CCR5 
promoter in hematopoietic cell lineages warrants further investigation. 
It is likely that the functional correlate of reduced CCR5 expression 
mediated by GATA-1, namely the inhibition of R5-tropic HIV-1 infection and viral 
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replication in T cells, will be evident in other HIV-1 target cells. However, the 
expression of GATA-1 is highly restricted during hematopoiesis and is not 
physiologically expressed in peripheral T cells, iNKT cells or DCs (data not 
shown). It is conceivable, however, that GATA-1 expression may be transiently 
induced in these cell types by specific activation signals, which could then 
influence the expression of CCR5. In a more likely scenario, GATA-1, which is 
clearly expressed in HSCs and is silenced upon their differentiation to CCR5-
expressing DCs (Fig. 1), may play a physiologic role in modulating HIV-1 
susceptibility of these cell types during hematopoietic development, as well as 
mast cell progenitors, which are all potential targets of viral infection in vivo (248, 
260, 261). A better understanding of GATA-1-mediated CCR5 repression opens 
the door to exciting new therapeutic approaches to down-regulate CCR5 in HIV-1 
infected individuals. 
In addition to the CCR5 inhibitory activity, ectopic expression of GATA-1 
was more potent at down-regulating IFNγ and CXCR3 expression compared to 
GATA-3, even in lineage-committed TEM cells. These findings highlight a 
remarkable ability to reprogram the expression of Th1 cytokines and chemokine 
receptors in human TEM cells, which are relevant in the context of T cell-mediated 
pathologies such as in autoimmune diseases and allograft rejection (87). 
Mechanistically, these findings suggest that the divergent N- and C-terminal 
portions of GATA-1 and GATA-3 differentially influence the expression of Th1-
associated cytokines and chemokine receptors. We speculate that three potential 
mechanisms may explain the differential activity of GATA-1 as compared to 
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GATA-3. First, the non-conserved trans-activation domains of GATA-1 may serve 
as additional protein interaction interfaces (262), which could allow it to 
selectively recruit repressive co-factors to the IFNγ and CXCR3 promoters. 
Second, the TF friend of GATA (FOG-1), which can interact with both GATA-1 
and GATA-3, might differentially regulate their function. Whereas FOG-1 
interaction with GATA-1 is required for its activity during erythropoiesis and 
megakaryopoiesis (117), it has been shown to inhibit the function of GATA-3 
during T cell differentiation (120). Therefore, the interaction of these GATA TFs 
with FOG-1 may impart differential regulation of Th1-associated gene 
expression. Finally, It is also plausible that GATA-1 and GATA-3 may be 
differentially phosphorylated, acetylated or methylated within these trans-
activation domains, resulting in unique regulation of Th1 gene expression (123, 
263, 264). Future structure/function studies utilizing chimeric GATA TFs may be 
useful to uncover specific GATA regulatory domains and auxiliary transcription 
factors that determine the expression of Th1 chemokine receptors and cytokines.  
While ectopic expression of GATA-1 is much more potent than GATA-3 in 
repressing the expression of CCR5 and other Th1 effector molecules, it is highly 
similar to GATA-3 in inducing Th2 cytokines (IL-4, IL-5, IL-13) and chemotactic 
receptors (CCR4 and CRTH2) (Table 4-2). In contrast to a previous study 
performed in murine T cells (257), we found that the regulation of Th2 cytokines 
and chemokine receptors was a direct function of GATA-1, occurring without 
trans-activation of GATA-3 expression. Thus, it seems likely that GATA-3 
expression is differentially regulated in mouse and human T cells. Our findings 
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strongly suggest that the conserved DNA binding zinc-finger domain shared 
between these GATA TFs is largely sufficient to program Th2 effector functions 
and lymphoid homing propensities.  
In summary, we have discovered that GATA-1 is a potent repressor of 
CCR5 expression in multiple human cell types that are physiologically targets of 
HIV-1 in vivo. Decoding the mechanisms underlying the functional similarities 
and differences between GATA-1 and GATA-3 in programming human Th2 
differentiation and repressing CCR5 expression have implications in 
understanding the molecular regulation of CCR5 expression, as well as other loci 
that contain GATA-responsive cis-sites. Importantly, these findings raise the 
unique possibility of harnessing the mechanisms by which GATA-1 mediates the 
repression of CCR5 as a therapeutic modality to render human T cells refractory 
to HIV-1 infection.  
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CHAPTER V 
 
 
INHIBITION OF ACTIVATION-INDUCED T CELL PROLIFERATION BY 
HELICOBACTER PYLORI VACUOLATING TOXIN IS INDEPENDENT OF 
EFFECTS ON IL-2 SECRETION 
 
 
Abstract 
 
Recent evidence indicates that the secreted Helicobacter pylori VacA toxin 
inhibits the activation of T cells. VacA blocks IL-2 secretion in transformed T cell 
lines through the suppression of NFAT activation. In this study we investigated 
the effects of VacA on primary human CD4+ T cells. VacA treatment of primary 
human T cells activated through the T cell receptor and CD28 resulted in potent 
inhibition of proliferation, without inhibiting IL-2 secretion or NFAT activation. 
VacA suppressed IL-2-induced cell-cycle progression and proliferation of primary 
human T cells, but did not affect IL-2-dependent survival. Through the analysis of 
a panel of mutant VacA proteins, we demonstrate that VacA-mediated inhibition 
of T cell proliferation requires an intact amino-terminal hydrophobic region 
necessary for the formation of anion-selective membrane channels. Remarkably, 
we demonstrate that one of these mutant VacA proteins (VacA-∆6-27) abrogates 
the immunosuppressive actions of wild-type VacA in a dominant negative 
fashion. These results reveal that VacA inhibits the proliferation of primary 
human T cells by a mechanism distinct from that described in transformed T cell 
lines. Our findings suggest that H. pylori may utilize this mechanism to inhibit 
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clonal expansion of T cells that have already been activated by H. pylori 
antigens, thereby evading the adaptive immune response and establishing 
chronic infection. 
 
Introduction 
 
Helicobacter pylori is a gram-negative, spiral-shaped, microaerophilic bacterium 
that colonizes the gastric mucosa of more than 50% of the human population 
(131, 132). H. pylori colonization can persist for decades in the absence of 
antibiotic treatment. Furthermore, infection with this bacterium is consistently 
associated with gastric mucosal inflammation, and is a risk factor for the 
development of peptic ulcer disease, distal gastric adenocarcinoma, and gastric 
lymphoma (131, 132). 
Most H. pylori strains secrete a vacuolating cytotoxin (VacA) into the 
extracellular space (265, 266). Epidemiological studies and experiments using 
animal models have suggested that VacA is an important H. pylori virulence 
factor in the pathogenesis of peptic ulceration and gastric cancer (267-271). 
Incubation of VacA with cultured mammalian cells has been shown to induce 
formation of intracellular vacuoles, depolarization of the cellular membrane 
potential, permeabilization of epithelial monolayers, apoptosis, detachment of 
epithelial cells from the basement membrane, and interference with the process 
of class II antigen presentation (265, 266). Many of these effects are dependent 
on the capacity of VacA to form anion-selective membrane channels (272-276). 
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VacA has also been reported to alter the expression of syntaxin 7 (277), and to 
induce the activation of p38-mediated signaling pathways (137, 278). 
H. pylori persists in the human gastric mucosa for decades despite the 
development of gastric mucosal inflammation and specific antibody production. 
Several lines of evidence indicate that CD4+ T cells are critical for protection 
against H. pylori colonization (133, 135, 279, 280). Thus, it seems possible that 
immune evasion strategies of H. pylori may involve the inhibition or modulation of 
T cell immunity. Indeed, two reports have recently demonstrated that VacA 
inhibits activation of Jurkat T cells (a human T cell lymphoma/leukemia cell line) 
as well as human peripheral blood lymphocytes (136, 137). Studies of Jurkat T 
cells indicate that VacA blocks TCR-mediated activation of the nuclear factor of 
activated T cells (NFAT), a key transcription factor required for optimal T cell 
activation (136, 137). The process by which VacA inhibits NFAT activation in 
Jurkat T cells is reportedly similar to the actions of the immunosuppressive drugs 
cyclosporine A and FK-506, which inactivate the NFAT phosphatase calcineurin 
(136). However, the process by which VacA inhibits activation of primary human 
CD4+ T cells has not yet been studied in any detail. 
In this report, we show that VacA inhibits the proliferation of primary 
human CD4+ T cells without affecting IL-2 expression or NFAT activation. In 
addition, we show that VacA suppresses IL-2-induced cell cycle progression 
without affecting IL-2-dependent survival. We also show that VacA-mediated 
inhibition of primary T cell proliferation is dependent on an intact VacA amino-
terminal hydrophobic domain required for membrane channel formation, and that 
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a mutant toxin lacking this domain blocks the T cell-suppressive action of wild-
type VacA in a dominant negative manner. These findings indicate that VacA can 
inhibit proliferation of primary human T cells by a mechanism distinct from that 
described in transformed T cell lines. 
 
Materials and Methods 
 
Purification of VacA  
H. pylori strains (wild-type strain 60190 and isogenic mutant strains) were grown 
as described (273, 275). Oligomeric forms of VacA were purified from broth 
culture supernatants of H. pylori as described (281). All experiments were 
performed using acid-activated preparations of VacA or acidified buffer control 
(PBS), unless stated otherwise. The final VacA concentration was 10 µg/ml for all 
the experiments, unless stated otherwise. For the dominant-negative assays, 
wild-type VacA was mixed with varying concentrations of VacA mutant toxins and 
the mixtures were acid-activated prior to addition of these samples to cells (275). 
 
Primary human T cell purification and Carboxy Fluorescein Diacetate 
Succinimide Ester (CFSE) labeling  
 
Resting CD4+ human T cells were purified from healthy adult donors as 
previously described (60). The purified cells were 99% CD3+CD4+ as assessed 
by staining and flow cytometric analysis. Cell proliferation was monitored by 
labeling T cells with 5 µM CFSE (Molecular Probes) before stimulation with α-
CD3/α-CD28 antibodies. 
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Primary human T cell purification and activation  
 
Activation of T cells was accomplished using anti-CD3 (OKT3, ATCC) and anti-
CD28 antibodies (BD Biosciences) (hereafter termed TCR stimulation) as 
described (60). Cells were removed from the activation signals after 48 hours 
and expanded in media supplemented with recombinant human IL-2 (Chiron, 200 
U/ml). Activated T cells were cultured as described previously (60). Jurkat T cells 
were TCR/CD28-stimulated as described above, or with phorbol myristate 
acetate (PMA, 50 ng/ml; Sigma) and ionomycin (500 ng/ml; Sigma), and 
maintained in RPMI media containing 10% FCS. To inhibit TCR/CD28 
stimulation, T cells were treated with the following immunosuppressive drugs: 
cyclosporine A (50 nM, Alexis Biochemicals), FK506 (100 nM, Alexis 
Biochemicals), or rapamycin (200 ng/ml, Alexis Biochemicals). 
 
FACS Analysis and IL-2 detection  
IL-2 receptor (CD25) surface expression was detected by staining with 
phycoerythrin (PE)-conjugated anti-human CD25 (BD Biosciences) as described 
previously (60). IL-2 secretion into culture supernatants was determined using 
cytometric bead array (CBA) according to the manufacturer’s instructions (BD 
Biosciences), and analyzed using CBA 6-bead analysis software (BD 
Biosciences). Samples were analyzed on a FACSCalibur® four color cytometer, 
using the CellQuest program. Live cells were gated based on forward and side 
scatter properties and analysis was performed using Cellquest software (BD 
Biosciences) as described previously (60). 
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Generation and use of NFAT reporter primary human T cells  
To generate primary human CD4+ T cells that expressed an NFAT transcriptional 
reporter, three tandem copies of the NFAT binding site of the IL-2 promoter were 
sub-cloned upstream of the EGFP gene (Clontech) to direct its transcription 
(282). This NFAT-GFP expression cassette was cloned into a lentiviral vector in 
reverse orientation and VSV-G pseudotyped viruses were generated via co-
transfection of 293 T cells as described previously (60). Activated primary CD4+ 
T cells were transduced with these pseudotyped viruses at a suboptimal MOI. 
After 7 days, cells constitutively expressing GFP were removed by FACS sorting 
and GFP-negative cells were stimulated with anti-CD3 and anti-CD28 antibodies 
for 24 hours. NFAT-GFP T cells that up-regulated GFP upon activation were 
positively sorted by flow cytometry and further expanded in IL-2-supplemented 
media. Following enrichment, ~10% of the NFAT-GFP T cell population displayed 
GFP-inducible expression upon TCR stimulation. 
 
Cell cycle analysis of T cell proliferation  
Activated T cells were washed to remove exogenous IL-2 and maintained in IL-2 
free medium for 24 hours to synchronize cells at phase G1 of the cell cycle. 
During this period, the cells were treated with VacA or other additives. Following 
incubation in IL-2-containing medium for the indicated time, cells were subjected 
to propidium iodide (PI) staining and analyzed by flow cytometry as described 
previously (283). To evaluate DNA replication, T cells were washed to remove IL-
2, and treated with VacA. Following VacA treatment, cells were incubated for 24 
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hours in IL-2 medium. 10µM 5-bromo-2-deoxyuridine (BrdU) was added to the 
cultures, and cells were harvested at different time points for BrdU antibody 
staining with a commercially available kit (BD biosciences). 
 
Results 
 
VacA inhibits activation-induced proliferation of primary human CD4+ T cells  
Previous reports have indicated that VacA inhibits T cell activation (136, 137). 
These studies clearly demonstrated that the suppressive effect of VacA on a 
transformed T cell line (Jurkat T cells) is due to interference with NFAT 
activation, resulting in the inhibition of IL-2 secretion. While several experiments 
were performed on unfractionated peripheral blood leukocytes, the mode of VacA 
action on purified primary T cells was not assessed (136, 137). To investigate 
whether VacA inhibits the activation of primary T cells in a manner similar to its 
effect on transformed cells, we purified CD4+ primary human T helper (Th) cells 
from peripheral blood mononuclear cells (PBMC) of healthy individuals and 
labeled them with CFSE, a cell-permeable dye that allows for the quantification of 
cell division within a population. CFSE-labeled Th cells were pre-treated with 
media, PBS, or VacA, followed by TCR stimulation using anti-CD3 and anti-CD28 
antibodies for 48 hours. After TCR stimulation, cells were expanded in IL-2-
containing media for an additional 3 days. As expected, Th cells pre-treated with 
media or PBS rapidly proliferated, resulting in up to 7 divisions when analyzed at 
5 days post TCR-activation (Fig.5-1A and 5-1B). In contrast, treatment with VacA 
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potently inhibited the proliferation of Th cells (Fig. 5-1A and 5-1B) in a dose-
dependent manner (Fig. 5-1C). Incubation of purified VacA at acid pH (pH <4.5; a 
process termed acid-activation) markedly enhances the capacity of the toxin to 
undergo internalization and cause vacuolating cytotoxic effects in HeLa or gastric 
epithelial cells (284, 285). Accordingly, the pH of VacA preparations were 
adjusted to either pH 3 or pH 7.5 (with HCl or PBS) prior to treatment of Th cells 
as described above. As shown in figure 5-1D, acid-activation markedly enhanced 
the capacity of VacA to inhibit Th cell proliferation. 
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Figure 5-1. VacA inhibits activation-induced proliferation of primary human 
CD4+ Th cells. 
A) Purified primary human Th cells were labeled with CFSE and treated with 
acid-activated VacA (10 µg/ml), acidified-PBS (PBS), or medium alone for 1 hour, 
followed by TCR stimulation with α-CD3/ α-CD28 antibodies for 48 hours as 
described in Materials and Methods. Activated T cells were expanded in IL-2-
containing media and T cell proliferation was analyzed at day 5 post-activation by 
flow cytometry. B) Graphic representation of the histograms shown in panel A. C) 
Dose-response analysis of VacA effects on primary human CD4+ T cell 
proliferation. Th cells were CFSE-labeled and treated with different 
concentrations of acid-activated (pH 3) VacA for 1 hour. Cells were then 
stimulated and analyzed as in panel A. D) Effects of acid-activated VacA (pH 3) 
and non-acid-activated VacA (pH 7.5) on T cell proliferation. Th cells were CFSE-
labeled and treated with acid-activated or non-activated VacA (10 µg/ml) as 
described above. All the results are representative of three experiments using 
cells from different donors and different toxin preparations. 
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VacA potently suppresses IL-2 secretion in Jurkat T cells, but not in primary 
human Th cells  
 
It has been reported recently that VacA blocks the secretion of interleukin-2 (IL-2) 
by mitogen-stimulated Jurkat T cells (136). Therefore, we investigated whether 
VacA also inhibits IL-2 secretion in primary Th cells. In agreement with a 
previous report (136), we found that wild-type VacA potently suppressed IL-2 
secretion in Jurkat T cells, very similar to the immunosuppressive drugs 
cyclosporine A and FK506, regardless whether the cells were stimulated with 
anti-CD3 and anti-CD28 antibodies or stimulated with PMA and ionomycin (Fig. 
5-2A and data not shown). Notably, a VacA mutant toxin deficient in vacuolating 
cytotoxic activity (VacA ∆6-27) (275) (Table 5-1) did not inhibit IL-2 secretion in 
Jurkat T cells (Fig. 5-2A). In contrast to the strong effects of wild-type VacA on 
IL-2 secretion by Jurkat T cells, VacA had a very modest effect on IL-2 secretion 
by primary human Th cells (Fig. 5-2A). TCR stimulation of T cells induces the 
expression of both IL-2 and the high affinity IL-2 receptor anti-chain (CD25). 
Therefore, we next investigated whether VacA treatment inhibited the surface-
expression of CD25. Primary human Th cells were pre-treated as described 
above and CD25 expression was analyzed both at 24 hours and 5 days post 
TCR stimulation by flow cytometric analysis. No significant difference was 
observed in CD25 expression between VacA-treated primary human T cells and 
those treated with PBS or media (data not shown). Although VacA treatment did 
not cause a biologically significant reduction in the amount of IL-2 produced, we 
further supplemented these cultures with saturating concentrations of exogenous 
recombinant IL-2 (50 ng/ml) during the activation. Resting Th cells were pre-
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treated with PBS, wild-type VacA, or VacA-∆(6-27) in the presence of exogenous 
IL-2 for 1 hour prior to TCR-activation. These pretreated cells were then TCR 
stimulated with anti-CD3 and anti-CD28 antibodies in the presence of IL-2-
containing media, and proliferation was analyzed 5 days after stimulation. VacA 
potently inhibited the proliferation of Th cells, even in the presence of excess 
exogenous IL-2 (Fig. 5-2B). Thus, we conclude that the VacA-mediated inhibition 
of primary human Th cell proliferation cannot be attributed to a VacA-induced 
reduction in IL-2 secretion. 
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Table 5-1: Functional characterization of VacA mutant toxins. 
 
 
a Oligomer formation was analyzed by determining whether these proteins eluted 
as large oligomeric structures (~1,000 kDa) from a gel filtration chromatography 
column (11, 12). 
b Binding and internalization of VacA toxins was assessed by indirect 
immunofluorescence analysis using HeLa cells (10, 45). 
c VacA channel activity was assessed using planar lipid bilayers (11-13). 
d Toxins (20 µg/ml) that induced vacuolation in more than 50% of HeLa cells were 
scored positive for cytotoxic activity (11, 12). 
e WT, wild-type VacA from H. pylori strain 60190. 
 
126 
 
 
Figure 5-2. VacA inhibits activation-induced proliferation of primary human 
Th cells independent of effects on IL-2 secretion and NFAT activation. 
A) Purified primary human Th cells or Jurkat T cells were pre-treated with media, 
wild-type (WT) VacA, VacA-∆(6-27), cyclosporine A (CspA), or no additive for 1 
hour, followed by TCR stimulation with a-CD3/a-CD28 antibodies (top panels) or 
with PMA (50 ng/ml) and ionomycin (500 ng/ml) (middle panels), as indicated. IL-
2 secretion was measured at 24 hours after stimulation using a cytometric bead 
array (CBA) as described in Materials and Methods. Results represent the mean 
+ S.D. from triplicate samples. B) Purified primary human Th cells were CFSE-
labeled and pretreated with wild-type VacA or PBS in the presence or absence of 
supplemental IL-2 for 1 hour as indicated. Cells were then TCR stimulated with 
antibodies for 48 hours, expanded in IL-2 supplemented media, and subjected to 
flow cytometric analysis at day 5 post-treatment. C) Primary human Th cells 
stably transduced with a GFP reporter under the control of NFAT (NFAT-GFP Th 
cells; see Materials and Methods) were pre-treated with the different conditions 
as in panel A for 1 hour prior to TCR stimulation with cross-linking antibodies. 
GFP expression was assessed by flow cytometric analysis 24 hours after 
stimulation. Results represent the mean + S.D. from triplicate samples and are 
expressed as the percentage of cells demonstrating inducible expression of GFP, 
relative to the PBS-treated cells. CspA, cyclosporine A (50 nM); WT, wild-type 
VacA toxin (10 µg/ml); and ∆6-27, VacA-∆(6-27) mutant toxin (10 µg/ml). 
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VacA inhibits primary human T cell proliferation through an NFAT independent 
mechanism 
 
VacA has been shown to inhibit NFAT activation in Jurkat T cells, resulting in a 
loss of IL-2 secretion (136, 137). However, since VacA has only minimal effects 
on IL-2 secretion in primary T cells upon stimulation (Fig 5-2A), we hypothesized 
that VacA-mediated inhibition of primary human T cell proliferation may occur via 
an NFAT-independent mechanism. To test this hypothesis, we developed a 
primary human Th cell stably transduced with a lentiviral vector in which the 
NFAT binding site of the IL-2 promoter drives the expression of the green 
fluorescent protein (NFAT-GFP T cells). NFAT-GFP T cells were treated with 
wild-type VacA, PBS, cyclosporine A, FK506, or VacA-∆(6-27) for 1 hour prior to 
stimulation with anti-CD3 and anti-CD28 antibodies. GFP expression was then 
analyzed 24 hours-post stimulation via flow cytometric analysis. As expected, 
GFP expression was only induced upon TCR-stimulation of NFAT-GFP T cells 
(Fig. 5-2C). In the presence of cyclosporine A or FK-506, which are potent 
inhibitors of NFAT activation, stimulated NFAT-GFP T cells did not express GFP 
(Fig. 5-2C and data not shown). In contrast, stimulated cells treated with VacA 
maintained the expression of GFP similar to the PBS-treated cells (Fig. 5-2C). 
These results, taken together with our findings that VacA causes minimal effects 
on IL-2 secretion in primary Th cells, suggest that VacA can inhibit proliferation of 
primary human Th cells via an NFAT-independent mechanism. 
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VacA inhibits IL-2-driven proliferation of primary human Th cells, but not IL-2-
dependent survival  
 
To gain further insight into the mechanism employed by VacA to suppress 
activation-induced proliferation of primary T cells, we investigated the kinetics of 
VacA-mediated effects. CFSE-labeled primary human Th cells were stimulated 
as previously described, and treated with PBS, wild-type VacA or VacA-∆(6-27) 
at different time points after TCR stimulation with anti-CD3 and anti-CD28 
antibodies. T cell proliferation was assessed 5 days after stimulation by flow 
cytometric analysis. VacA inhibited proliferation of Th cells even when added 48 
hours after stimulation, suggesting that VacA effects are largely independent of 
early TCR signals (Fig. 5-3A). In contrast, cyclosporin A and FK506 completely 
inhibited Th cell proliferation when added within the first 24 hours, but had little 
effect when added 48 hours after TCR stimulation (data not shown). 
We next tested whether VacA blocked IL-2 dependent proliferation of 
primary T cells at later time points (96 hours) after stimulation, a stage in which T 
cell proliferation and survival are solely dependent on IL-2 signals (286). For 
these experiments, Th cells were stimulated with anti-CD3 and anti-CD28 
antibodies for 48 hours and expanded in the presence of IL-2 for an additional 2 
days. At day 4 post-activation, T cells were removed from IL-2, and treated with 
VacA or other additives for 24 hours. IL-2 was then added back to the media and 
cells were expanded for an additional 3 days. Cell counts were performed to 
assess cellular proliferation at day 0- and day 3-post IL-2 stimulation. As 
expected, activated T cells treated with PBS and stimulated with IL-2 proliferated 
approximately 6-fold from day 0 to day 3, and no proliferation was observed in 
129 
the absence of IL-2 (Fig. 5-3B). In the presence of VacA, however, T cell 
numbers only increased about 3-fold (p < 0.001), similar to cells treated with 
rapamycin (Fig. 5-3B) that blocks IL-2 driven proliferation of T cells (287, 288). 
Analogous results were obtained when proliferation was assessed via CFSE-
fluorescence (data not shown). These data indicate that VacA inhibits IL-2 driven 
proliferation of activated primary human Th cells. 
IL-2 signals are required not only for activation-induced T cell proliferation, 
but also for survival of these cells (286). Therefore, we also monitored the 
viability of the activated Th cells cultured in the presence or absence of VacA. 
Indeed, the majority of activated T cells (>90%) kept without IL-2 for 3 days 
underwent apoptosis (Fig. 5-3C). In contrast, VacA treatment did not result in a 
significant increase in cell death as compared to T cells treated with PBS (Fig. 5-
3C), suggesting that VacA inhibits IL-2-driven proliferation without altering IL-2-
dependent survival. 
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Figure 5-3. VacA inhibits IL-2-driven proliferation of primary human Th 
cells.  
A) Wild-type (WT) VacA (10 µg/ml) and VacA-∆(6-27) (10 µg/ml) were added to 
CFSE-labeled purified primary human Th cells at the indicated time points either 
preceding or following (pre or post) TCR stimulated with α-CD3/ α-CD28 
antibodies. Activated cells were expanded in IL-2-containing media and cell 
proliferation was analyzed by flow cytometry at day 5 after stimulation. B) primary 
human Th cells were TCR stimulated using antibodies as in (A) for 48 hours and 
expanded in the presence of IL-2 for 2 additional days. At day 4 after stimulation, 
T cells were removed from IL-2 and treated with PBS, wild-type VacA (10 µg/ml), 
or rapamycin (Rap; 200 ng/ml) for 24 hours. After 24 hours, IL-2 was added back 
to the media as indicated and cells were treated again with the different additives 
and expanded in fresh media containing supplemental IL-2 for 3 days. Cell 
proliferation was assessed by cell counting with a hemacytometer. Results 
represent the mean + S.D. from triplicate samples. * = p < 0.001 when compared 
to the PBS treated cells. C) Th cell viability of the was determined by gating for 
viable cells based on forward and side scatter properties via flow cytometric 
analysis at day 1, 2, and 3 after stimulation with antibodies. D) For cell cycle 
analysis, primary human Th cells were treated as described in panel B. Cell-cycle 
distribution was analyzed at 36 hours following IL-2 stimulation using PI staining 
and flow cytometry analysis, as described in Materials and Methods. The 
percentages of total cells in S-phase and G2/M-phase are shown. Results 
represent the mean + S.D. from triplicate samples. * = p < 0.01 when compared 
to the PBS treated cells. Results are representative of at least two experiments 
using cells from different donors and different toxin preparations. 
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VacA attenuates IL-2-dependent cell cycle progression in primary human Th cells  
 
To determine whether VacA-mediated inhibition of IL-2-driven proliferation is due 
to a cell cycle arrest, we assessed cell cycle progression of activated T cells in 
the presence of VacA. Primary human Th cells were stimulated with anti-CD3 
and anti-CD28 antibodies, and expanded in IL-2- containing media as described 
above. Day 4-activated Th cells were removed from IL-2 for 24 hours to induce a 
G1-phase cell-cycle arrest (288), and were then treated with VacA or other 
additives. IL-2 was then added back to the media, and cell cycle distribution was 
analyzed at different time points through propidium iodide (PI) staining. The 
activated Th cells arrested in G1-phase re-entered the cell cycle approximately 
24 to 36 hours after IL-2 stimulation, as seen by the increased number of Th cells 
in S and G2M phases (Fig. 5-3D). In contrast, cells treated with either rapamycin 
(which inhibits IL-2-induced cell cycle progression by arresting the cells at the 
G1-phase) (287, 289) or VacA displayed impaired IL-2-induced cell cycle 
progression (Fig. 5-3D). We also determined the rate of DNA synthesis in VacA-
treated Th cells by assessing incorporation of BrdU, a thymidine analog that is 
incorporated into newly synthesized DNA during S-phase. VacA-treated activated 
T cells were about 2-fold less efficient in the rate of BrdU uptake when compared 
to PBS-treated control cells (data not shown), thus corroborating the PI results 
(Fig. 5-3D). Taken together, these data provide strong evidence that VacA 
inhibits IL-2-driven proliferation in activated primary human Th cells by inhibiting 
cell cycle progression. 
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The N-terminal hydrophobic domain of VacA is required for inhibition of primary 
human Th cell proliferation 
 
Structure-function analyses have revealed that an intact structure of a 
hydrophobic domain within the VacA amino-terminal region is required for the 
formation of anion-selective membrane channels (Table 5-1) (272-276). Because 
VacA-∆(6-27), a VacA mutant that lacks the entire hydrophobic domain, did not 
suppress proliferation of primary Th cells (Fig. 5-3A) or IL-2 secretion in Jurkat T 
cells (Fig. 5-2A), we hypothesized that the formation of VacA anion-selective 
channels plays an important role in the VacA-mediated inhibition of T cell 
activation-induced proliferation. To further test this hypothesis, we examined the 
effects of two VacA mutant toxins that contain single amino acid substitutions in 
the hydrophobic domain of VacA (VacA-P9A and VacA-G14A) (273) on 
proliferation of primary human Th cells. These VacA mutants proteins, including 
VacA-∆(6-27), are defective in channel-forming activity, but retain other structural 
and functional characteristics of the wild-type VacA protein, including the ability 
to form oligomeric structures and the capacity to bind and enter cells (Table 5-1) 
(273, 275, 276). In contrast to wild-type VacA, these mutant proteins did not 
cause any detectable inhibition of T cell proliferation (Fig. 5-4). These data 
indicate that an intact VacA amino-terminal hydrophobic domain is required for 
VacA-mediated inhibition of T cell proliferation, and suggest that the formation of 
VacA anion-selective membrane channels is important for the suppression of 
activation-induced proliferation of primary Th cells. 
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Figure 5-4. Analysis of VacA mutant proteins demonstrates that an intact N-
terminal hydrophobic domain is required for VacA-mediated effects on T 
cells. 
Purified primary human Th cells were CFSE-labeled and treated with wild-type 
VacA (WT; VacA at 10 µg/ml), one of 3 different mutant toxins (each 10 µg/ml), 
or PBS for 1 hour. Cells were then TCR stimulated with α-CD3/α-CD28 
antibodies for 48 hours, expanded in IL-2-containing media, and analyzed by flow 
cytometry at day 5 after stimulation as described in Materials and Methods. 
Results are representative of three experiments using cells from different donors 
and different toxin preparations. 
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VacA-∆(6-27) inhibits the immunosuppressive effects of wild-type VacA on T 
cells 
 
In studies of VacA-induced effects on HeLa cells and AGS cells (a human gastric 
epithelial cell line), the VacA mutant toxin (VacA-∆(6-27)) has been reported to 
exhibit a dominant-negative phenotype (275). When mixed in an equimolar ratio 
with wild-type VacA, VacA-∆(6-27) blocks the capacity of wild-type VacA to 
cause cell vacuolation (275), form anion-selective membrane channels (275), 
induce cytochrome c release (276), and induce apoptosis (290). The inhibitory 
actions of VacA-∆(6-27) are thought to be due to the formation of inactive mixed-
oligomeric complexes, comprised of both wild-type and mutant toxin (275, 291, 
292). To investigate whether VacA-∆(6-27) could block the actions of wild-type 
VacA on Th cells, the two toxins were mixed and added at various stoichiometric 
ratios to CFSE-labeled, resting Th cells. CFSE-labeled primary human Th cells 
were subsequently stimulated with anti-CD3 and anti-CD28, and proliferation was 
evaluated by flow cytometric analysis 5 days post stimulation. VacA-∆(6-27) 
potently blocked wild-type VacA-mediated inhibition of T cell proliferation in a 
dominant-negative fashion, since it was partially effective even in the presence of 
20-fold molar excess of wild-type VacA (Fig. 5-5A). Furthermore, VacA-∆(6-27) 
also blocked the inhibitory effects of wild-type VacA on IL-2 secretion in Jurkat T 
cells (Fig. 5-5B). Importantly, the dominant-negative phenotype exhibited by the 
VacA-∆(6-27) mutant toxin was specific for the ∆6-27 mutation, since two other 
mutant toxins containing point mutations within the VacA N-terminal hydrophobic 
domain (P9A and G14A) did not exhibit a dominant-negative phenotype (data not 
shown). 
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Figure 5-5. Effects of a dominant-negative mutant VacA toxin.  
A) Primary human Th cells were CFSE-labeled and then treated for 1 hour with 
wild-type VacA (10 µg/ml) and VacA-∆(6-27) in different ratios (WT:∆6-27) as 
indicated. Cells were then TCR stimulated with α-CD3/ α-CD28 and expanded in 
IL-2-supplemented media as described in Materials and Methods. Cell 
proliferation was analyzed by flow cytometric analysis on day 5 after stimulation. 
B) Jurkat T cells were pre-treated as in panel A with the different conditions for 1 
hour as indicated, activated with PMA (50 ng/ml) and ionomycin (500 ng/ml), and 
then incubated for 24 hours. Culture supernatants were assayed for IL-2 
secretion using a cytometric bead array (CBA) assay as described in Materials 
and Methods. Results are representative of three experiments using cells from 
different donors and different toxin preparations. 
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Discussion 
 
Here we show that VacA inhibits the proliferation of primary human CD4+ Th cells 
upon TCR/CD28-stimulation (Fig. 5-1). In addition, our data demonstrate a 
qualitative difference between VacA-mediated effects on IL-2 secretion by Jurkat 
T cells and primary human Th cells (Fig. 5-2). In contrast to its potent inhibitory 
effects on IL-2 production in Jurkat T cells (Fig. 5-2A) (136, 137), VacA-treated 
primary human T cells retain the capacity to secrete high levels of IL-2 (Fig. 5-
2A). The suppressive effect of VacA on Jurkat T cell proliferation has been 
previously attributed to the suppression of IL-2 expression, occurring at the level 
of transcriptional regulation due to NFAT inhibition (136, 137). In contrast, our 
results provide evidence that VacA-mediated inhibition of primary human Th cell 
proliferation occurs at a later stage of T cell activation, wherein the 
immunosuppressive drugs cyclosporine A and FK-506 (NFAT activation 
inhibitors) are no longer inhibitory (Fig. 5-3A, 5-3B and data not shown). 
Specifically, we show for the first time that VacA impairs IL-2-induced cell-cycle 
progression in activated primary human Th cells (Fig. 5-3B), resulting in an 
inhibition of IL-2-driven proliferation. Indeed, the inhibitory activity of VacA on IL-
2-driven T cell proliferation appears similar to the actions of the 
immunosuppressive drugs rapamycin and sanglifehrin A (287, 293), two known 
inhibitors of IL-2 proliferation. 
We also show, based on analysis of single-point mutant toxins, that the 
inhibitory effect of VacA on primary human Th cell proliferation and IL-2 secretion 
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in Jurkat T cells is dependent on the integrity of the VacA N-terminal hydrophobic 
domain. Three different mutant toxins defective in membrane channel formation 
were each unable to inhibit the proliferation of primary human Th cells (Fig. 5-4), 
providing strong evidence that VacA-mediated effects on T cell proliferation are 
dependent on the formation of membrane channels. Further evidence in support 
of this conclusion is provided by experiments with a dominant-negative mutant 
VacA protein, VacAΔ(6-27) (275), which potently blocked the effects of wild-type 
VacA on T cells (Fig. 5-5). This dominant-negative VacA protein interacts with 
wild-type toxin, resulting in the formation of non-functional mixed-oligomeric 
structures (273, 275, 291). Inhibition of wild-type VacA activity by a dominant 
negative mutant protein is consistent with a model in which the formation of 
oligomeric VacA structures, such as membrane channels, is required for VacA-
induced effects on T cells. We hypothesize that formation of anion-selective 
VacA membrane channels (272, 274) induces membrane-depolarization of T 
cells, resulting in an altered equilibrium of numerous ions, and that these 
phenomena are mechanistically important in the inhibition of IL-2-dependent T 
cell proliferation. Our hypothesis is supported by a previous study demonstrating 
that activation of glycine-gated chloride channels induces membrane 
depolarization of T cells, resulting in a decreased open probability of plasma 
membrane calcium channels and in the inhibition of IL-2-dependent proliferation 
without affecting IL-2 secretion or NFAT activation (294). 
Gastric biopsies from H. pylori-infected individuals consistently 
demonstrate infiltration of CD4+ T helper cells (134, 279, 280), and specific anti-
138 
H. pylori T cells have been detected in the gastric mucosa (134, 295). 
Nevertheless, H. pylori is able to evade the immune response and establish 
persistent infection. Experiments in mice indicate that the quality of the Th cell 
response is critically important for eradication of H. pylori and prevention of H. 
pylori-induced pathology (133, 135). Based on the results of the current study, 
we propose that VacA can inhibit the clonal expansion, and thus the acquisition 
of effector functions of T cells that have already been activated by H. pylori 
antigens. This immunosuppressive activity of VacA is likely to play an important 
role in the process by which H. pylori evades the adaptive immune response. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The human immune system is a complex, hierarchical network of symbiotic cells 
that coordinate protection against parasitic microorganisms. Defensive barriers, 
immune surveillance and immediate inflammatory responses at anatomical sites 
of pathogenic invasion are mediated by the innate immune system. However, a 
cardinal feature of immunity in higher vertebrates is the ability to mount 
qualitatively distinct responses to discrete pathogens, an attribute ultimately 
determined by the differentiation of CD4+ Th cells from naïve to effector and 
memory subsets. In this respect antigen-specific Th cells are analogous to 
military field generals, mobilizing and regulating the various arms of the human 
immune forces. On the other hand, successful pathogens that have remained 
prevalent throughout the human population have co-evolved an intricate series of 
immune evasion tactics, which often involve the perturbation or usurpation of Th 
cell development and function in order to thrive under intense selective immune 
pressures. As such, further elucidating how human Th cells differentiate, gain 
effector function and interact with microbial pathogens is important to understand 
what makes an immune response protective, ineffective or pathogenic and may 
identify how such responses can be therapeutically manipulated.  
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Flexible programs of human Th cell differentiation 
Our findings detailed in chapter II demonstrate that lineage-committed primary 
human memory Th cells can be genetically reprogrammed towards Th2 or Th1 
type cells by expression of the transcription factors GATA-3 and T-bet, 
respectively (60). Transduction of GATA-3 in TN and TCM cells induce cytokine 
and chemokine receptor expression patterns ascribed to Th2 cells. However, 
GATA-3 fails to significantly down-regulate IFNγ production and IL-12Rβ2 
expression in cells already committed to the Th1 lineage and in the TEM subset. 
T-bet expression directs TN and TCM human T cells to a Th1 phenotype, while it 
was much less effective at modifying the effector functions of TEM cells. These 
data suggest a progressive loss in functional flexibility as Th cells mature from 
naïve to effector memory subsets (60).  
These findings support a model of Th cell differentiation wherein TCM cells 
represent an antigen-primed subset, which is capable of modifying its lineage 
commitment upon antigenic stimulation to generate new waves of TEM cells (44, 
47, 60, 156). On the other hand, differentiated TEM cells, which have already 
been programmed to mount specific responses to an invading pathogen, more 
significantly lack adaptability to environmental cues that less differentiated TCM 
cells exhibit. However, we show that effector function and chemokine receptor 
expression can even be partially modified in TEM cells, most strikingly in response 
to forced GATA-1 and T-bet expression. These findings suggest that over the 
course of an immune response antigen-specific memory Th cells can modulate 
their effector functions and lymphoid trafficking propensities according to the 
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milieu of differentiating signals present in the extracellular micro-environment (47, 
60, 68, 83, 86, 296). Indeed, adaptable memory responses exhibiting plasticity in 
the context of antigen re-exposure could be a highly beneficial strategy against 
continually evolving pathogens. Together, these findings lend novel insight into 
the differentiation programs of human Th cells and may also have implications in 
the development of new therapeutic strategies to ameliorate immunopathologies 
stemming from misbalanced memory T cell responses. 
Future studies will aim to further dissect the mechanisms underlying the 
progressive loss of Th cell functional plasticity during their differentiation to 
effector and memory subsets. However, given the biologically complex nature of 
Th cell differentiation we posit that Occam’s razor is not applicable. Rather, we 
propose and will test a three-part hypothesis wherein each component 
contributes to the sum that manifests as the progressive loss of functional 
plasticity during Th cell differentiation. We theorize one contributing factor is the 
chromatin remodeling of key cytokine promoter loci that is associated with TN cell 
differentiation to effector and memory cells (82, 83, 164, 297). We propose such 
structural reorganization of these loci either modifies the regulatory activities of T-
bet or GATA-3 by changing the interactive partners present within the 
transcription complexes or simply precludes these factors from binding their 
cognate cis-elements (298). To this end, future biochemical studies will monitor 
Th1- and Th2-specific chromatin remodeling at the IL-4 and IFNγ cytokine gene 
promoters as TN cells differentiate to polarized effector and memory subsets, 
aiming to identify specific modifications within these loci that are associated with 
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the loss of functional plasticity exhibited by effector and memory T cells upon 
expression of the opposing master transcription factor. These experiments will 
begin to unravel the “histone code” that regulates the acquisition and 
maintenance of Th cell effector function (299-302). 
A second hypothesis that could, in part, account for the progressive 
inability of T-bet and GATA-3 to fully reprogram antigen-specific memory Th cells 
is that these master transcription factors require synergistic activities of auxiliary 
co-factors whose expression is lost or who become non-functional as TN cells 
differentiate to effector and memory subsets. Indeed, a number of transcription 
factors aside from T-bet and GATA-3 have been identified that influence the 
Th1/Th2 balance (73, 81, 120, 144, 146, 147, 157, 163, 165, 166, 303-308). 
However, experiments carefully scrutinizing the expression of these factors in 
naïve and memory Th cell subsets have not been performed. Additionally, given 
the vast scale of differential gene expression that is associated with Th cell 
differentiation (309, 310), we consider it likely that additional Th cell 
transcriptional regulators remain unidentified. Indeed, we have found that T-bet 
down-regulates c-maf, a Th2-specific transcription factor that synergistically 
promotes high-level IL-4 production with GATA-3 (our unpublished data and refs 
((146-148)). These findings suggest the expression and activity of c-maf and 
other auxiliary Th1/Th2 transcription factors in naïve and memory T cell subsets 
may help determine the extent to which their effector functions can be modified. 
Therefore, to address the relative contribution of accessory transcription factors 
in this context, future studies will feature an innovative co-transduction approach. 
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For these experiments, known Th cell regulatory transcription factors such as 
STAT-4, STAT-6, NFATc2, c-maf, NFκB, FOG, ROG, SKAT-2 and Hlx (73, 81, 
120, 144, 146, 147, 157, 163, 165, 166, 303-308) will be expressed in lineage-
committed effector and memory Th cells in conjunction with T-bet or GATA-3 to 
determine if specific combinations of master and auxiliary transcription factors 
can more completely reprogram the effector functions of lineage-committed 
effector and memory Th cells. In addition, we have performed gene expression 
profiling of Th1 and Th2 cells using oligonucleotide micro-arrays and have 
generated lists of potential Th1 or Th2 transcriptional regulators (unpublished 
data). Similar to the studies using known Th cell transcription factors, candidate 
regulatory genes will be co-expressed with T-bet or GATA-3 in effector or 
memory cells committed to the opposing lineage to identify new auxiliary 
Th1/Th2 transcription factors.  
The third and final component we hypothesize to play a role in the 
progressive loss of functional plasticity during Th cell differentiation is the co-
repressive nature of T-bet and GATA-3. Several studies characterizing the 
master regulatory roles of T-bet and GATA-3 clearly demonstrate that T-bet 
expression in Th1 and GATA-3 expression in Th2 effector and memory Th cells 
actively represses development of the opposing T cell lineage (60, 79, 95, 104, 
107-109, 122, 233, 311). Our experiments show that even forced expression of 
these factors off of lentiviral transgenes cannot completely reprogram lineage-
committed Th cells (60), strongly suggesting that cross-inhibition between T-bet 
and GATA-3 is not solely at the level of inhibiting gene expression. However, it 
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remains plausible that T-bet and GATA-3 post-translationally inhibit each other 
either directly through physical interactions (122) or indirectly through the 
induction of T-bet/GATA-3 inhibitors (120, 166, 312). Indeed, in studies detailed 
herein, we show that as TN cells differentiate into Th1 effector cells, loss of T-bet 
expression results in more pronounced Th2 cytokine production and expression 
of Th2-associated chemokine receptors. These key results provide further 
evidence that T-bet, at least in part, functions to inhibit Th2 development and 
function. Therefore, to further characterize our T-bet/GATA-3 cross-inhibition 
hypothesis, future studies will utilize our recently developed RNAi system 
(chapter III) to co-express GATA-3 in conjunction with T-bet siRNA in Th1 
effector and memory cells. Likewise, T-bet will be expressed in the presence or 
absence of GATA-3 siRNA in Th2 lineage-committed cells. We predict that 
expression of these master transcription factors in lineage-committed TEM cells 
will result in more complete functional reversion upon silencing of the opposing 
factor. These experiments will lend further insight into the cross-regulatory roles 
of T-bet and GATA-3 during Th cell differentiation. Collectively these studies will 
begin to decode the transcription factor networks that regulate human Th cell 
differentiation programs and may lead to innovative therapeutic approaches to 
manipulate memory Th cell function in the context of infection or 
immunopathologies. 
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Mechanisms of gene regulation in human Th cells by GATA transcription factors 
GATA proteins comprise a six-member family (GATA-1-6) of transcription factors 
that play integral regulatory roles in cell ontogeny and function within a multitude 
of cell types and tissues (100, 110, 111). As such, GATA transcription factors are 
highly conserved across species, yet display only modest, highly modular 
conservation between individual family members. Specifically, GATA 
transcription factors are classified based on a highly conserved C4-type zinc-
finger motif (either one or two finger motifs) that mediates DNA binding and 
protein-protein interactions (226, 227, 313). GATA-1, -2, and –3 are closely 
related and all are key regulators of hematopoiesis in mammals (101, 138, 220, 
228-231). Remarkably, while GATA-1, -2, and –3 share significant sequence 
similarity within the zinc-finger domain that confers conserved DNA binding 
propensities for the consensus DNA element (A/T)GATA(A/G) (110-112, 232), 
homology in amino- and carboxy-terminal regions of the gene/protein located 
outside the zinc-fingers is minimal. In studies detailed in chapter IV, we have 
utilized the regions of structural conservation and divergence between GATA-1 
and GATA-3 to provide insight into the mechanism whereby GATA-3 regulates 
gene expression during human Th cell differentiation.  
We have shown that expression of GATA-1 in human naïve and memory 
Th cell subsets, similar to GATA-3, induces Th2 cytokine production (IL-4, IL-5, 
IL-13) and expression of the Th2 chemotactic receptors CCR4 and CRTH2. 
These findings strongly suggest the DNA binding zinc-finger domain of GATA-3 
is pivotal and largely sufficient to induce Th2 gene expression during Th cell 
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differentiation, as greater than 90% conservation within this domain of GATA-1 
confers redundant Th2 regulatory activity. Importantly, regulation of Th2 
cytokines and chemokine receptors occurred directly by GATA-1, without trans-
activating GATA-3 expression. The parallel regulation of Th2 cytokines and 
chemokine receptors by GATA-3 and GATA-1 indicate conserved DNA binding 
and interactions with auxiliary transcription factors mediated by the central zinc-
finger domain may be important in their trans-activation (236, 259).  
While redundant in their capacity to promote the expression of Th2-
associated genes, we note remarkably unique regulation of Th1 effector 
molecules by GATA-1. Expression of GATA-1 inhibits the production of IFNγ 
more so than GATA-3 and also prominently reduces the expression of the Th1-
associated chemokine receptors CXCR3 and CCR5, even in lineage-committed 
TEM cells. These results imply that domains lying in areas of significant 
divergence between GATA transcription factors (123, 263, 264, 314) can alter 
the expression of Th1 effector molecules. Indeed, amino- and carboxy-terminal 
portions of GATA transcription factors contain putative trans-activation domains 
that presumably function either as additional protein interaction interfaces or as 
acceptor sites for post-translational modifications (263, 264, 314-316). Thus, 
distinct trans-activation domains of GATA-1 and GATA-3 may impart differential 
regulation of IFNγ, CXCR3 and CCR5 by mediating unique interactions with 
transcription complexes within these promoter loci. Alternatively, GATA-1 and 
GATA-3 may be differentially modified within these domains, resulting in distinct 
regulatory activities (123, 263, 264, 314). Collectively, these findings indicate that 
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the domains of GATA transcription factors that control Th1 and Th2 effector loci 
may be discrete. 
Although a biologically useful and important comparison, our findings only 
yield hints as to the key regulatory domains within GATA-3 that controls gene 
expression during human Th cell differentiation. Thus, future structure/function 
studies utilizing chimeric GATA transcription factors will be pursued to uncover 
specific regulatory regions and potentially important auxiliary transcription factors 
that can determine the expression of Th1 cytokines and chemokine receptors. 
We hypothesize that a chimeric GATA-1 transcription factor containing the zinc-
finger domain of GATA-3 will be equally capable of down-regulating Th1 effector 
genes as wild-type GATA-1, whereas a GATA-3 protein with the zinc-finger 
domain of GATA-1 will remain unable to repress Th1 effector function. If our 
hypothesis holds true additional follow-up studies will generate a series of 
chimeras that more finely swap regions of the GATA transcription factors outside 
of the central zinc-fingers. Together these analyses may divulge the molecular 
mechanisms whereby GATA-3 controls gene expression in and effector function 
of human Th cells during immune activation. Such information could lead to the 
development of small-molecule inhibitors that could effectively target GATA-3 to 
stem the onset or pathogenesis of Th2-mediated atopic disorders. 
 
Regulating Th cell expression of CCR5 and susceptibility to HIV-1 infection 
Given the pivotal role of Th cells in regulating human immunity it is perhaps not 
surprising that numerous pathogens have counter-evolved immune evasion 
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strategies focused on disrupting Th cell differentiation and function. This strategy 
is exemplified by the human immunodeficiency virus (HIV). HIV-1 potently and 
selectively targets human Th cells for infection and eventual destruction through 
its keen tropism for biologically important receptors (CD4, CCR5, CXCR4) that 
are necessary for viral attachment and entry into host cells (126-128, 317-319). 
While CD4 is required for Th cell development and function and is thus 
constitutively expressed, the co-receptors CCR5 and CXCR4 are differentially 
expressed amongst naïve, effector and memory Th cell subsets (208, 317, 318). 
Of these two chemokine receptors usurped by HIV-1, CCR5 appears to be the 
most significant as the majority of natural HIV isolates are CCR5 (R5)-topic (320, 
321). Indeed, HIV-1-infected individuals carrying mutations within the CCR5 gene 
that precludes or reduces cell-surface expression are resistant to HIV-1infection 
or progression to AIDS, respectively (212-217). Moreover, active inhibition of 
CCR5 expression and function by intracellular immobilization (218), small-
molecule inhibitors (211) and siRNA (219) blocks in vitro HIV-1infection of Th 
cells. Thus, understanding the molecular regulation of CCR5 is paramount to 
developing effective anti-retroviral therapies. 
 Multiple consensus GATA-binding elements exist within the CCR5 
promoter locus (129, 130) and previous studies have shown GATA transcription 
factors can bind these sites (223), suggesting a potential regulatory role for 
GATA family members in CCR5 gene expression. Our studies in chapter IV 
provides novel evidence that GATA-1 is a potent inhibitor of CCR5 expression, 
even in highly differentiated CCR5+ TEM cells, iNKT cells and terminally 
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differentiated DCs, resulting in significant Th cell resistance to R5-tropic HIV-1 
infection and viral replication. Mechanistically, we demonstrate that GATA-1 
suppresses CCR5 cell-surface expression in human Th cells by potently 
silencing promoter activity, strongly suggesting that GATA-1 may be a master 
regulator of CCR5 gene expression. These key results expose GATA-1 as a 
potential therapeutic tool in the fight against HIV-1 and AIDS. 
However potent as a CCR5 repressor, the expression of GATA-1 is highly 
restricted during hematopoiesis and is not expressed in peripheral Th cells, iNKT 
cells or dendritic cells (our unpublished data and ref (220)). Therefore, the 
physiologic role of GATA-1 in regulating CCR5 expression and thus, 
susceptibility to HIV-1 in vivo remains uncertain. However, work from these 
studies and others have shown that GATA-1 is highly expressed in pluripotent 
CD34+ hematopoietic stem cells (HSCs), which are reportedly susceptible to HIV-
1 infection and are potential targets of viral infection in vivo (220, 237, 248, 260). 
Indeed, our findings that primary human HSCs silence GATA-1 expression and 
concomitantly up-regulate CCR5 upon differentiation to DC further supports our 
hypothesis that GATA-1 may a master regulator of CCR5 expression irrespective 
of cell type and suggest it may play a key physiologic role in regulating bone 
marrow precursor cell susceptibility to HIV-1 infection (322).  
Analyses of CCR5 promoter regions have revealed a plethora of putative 
transcription factor binding sites. In addition to GATA transcription factors, other 
transcription factors have been characterized that bind to cis-elements within the 
CCR5 promoter (129, 130), including octamer transcription factors (Oct-1, Oct-2) 
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and YY-1 (323, 324). While the overwhelming majority of these studies have 
been performed using transformed T cell lines and must be validated in the 
primary cell context, intricate transcriptional complexes of enhancers and 
repressors likely regulate CCR5 gene expression in human cells. Therefore, 
future studies will be performed to identify and functionally validate the roles of 
additional transcription factors in the regulation of CCR5. Complimentary sets of 
experiments using ectopic expression and siRNA-mediated silencing of 
candidate transcription factors in human Th cells will be used to evaluate how 
their expression influences CCR5 expression and susceptibility to HIV-1 
infection. Indeed, these experiments will help divulge the molecular regulation of 
CCR5 within human Th cells that ultimately determines the balance of 
susceptibility or resistance to HIV-1. 
 
Immunology lessons from a pathogen: using VacA to probe the molecular 
regulation of Th cell proliferation 
 
Another pervasive human pathogen that has evolved elaborate immune evasion 
strategies is the microaerophilic bacterium Helicobacter pylori. H. pylori colonizes 
the gastric mucosa of more than 50% of the human population (131, 132) and 
can persist for decades in the absence of antibiotic treatment. During infection, 
Th cells are critical for protection against H. pylori colonization (133-135, 279, 
280). Studies detailed here in chapter V demonstrate that a vacuolating cytotoxin 
produced by H. pylori, VacA, inhibits the activation-induced proliferation of 
primary human Th cells (325). We found that VacA inhibits activation-induced 
proliferation of human Th cells without affecting early TCR/co-stimulatory signals, 
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IL-2 production or up-regulation of the high-affinity alpha chain (CD25) of the IL-2 
receptor. Our findings were contrary to previous work investigating the 
immunosuppressive activities of VacA on a transformed T cell line that indicated 
the toxin blocked early activation signals by inhibiting NFAT activation, which in 
turn resulted in a diminution of IL-2 secretion and dampened expression of CD25 
(136, 137). These findings again highlight the functional discrepancies between 
transformed and primary T cells and demonstrate the value of investigating 
biological processes in their appropriate physiologic context. Our data further 
indicate that the mechanism whereby VacA inhibits growth of activated human 
Th cells is by attenuating IL-2-driven proliferation (325). 
 Mechanistically, structure/functional analysis of VacA requirements for its 
immunosuppressive activity on human Th cells demonstrates that mutant toxins 
defective in membrane channel formation are unable to inhibit the proliferation of 
primary human Th cells. Moreover, a dominant-negative mutant VacA protein 
that interacts with the wild-type toxin, resulting in the formation of non-functional 
mixed-oligomeric structures incapable of forming membrane channels (273, 275) 
blocks the inhibitory activity of wild-type VacA (325). Together, these key findings 
provide strong evidence that VacA-mediated effects on T cell proliferation are 
dependent on the formation of membrane channels. We hypothesize that 
formation of anion-selective VacA membrane channels (272, 274, 326) induces 
membrane-depolarization of T cells, resulting in an altered equilibrium of 
intracellular ions that are mechanistically important during IL-2-dependent T cell 
proliferation. Accordingly, a previous report shows that glycine treatment of 
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activated T cells inhibits IL-2-driven proliferation through the perturbation of 
chloride channels, causing membrane depolarization (294). Alternatively, the 
channel-forming domain of VacA may also contain interfaces that mediate host 
protein interactions that are obligate for the inhibition of Th cell proliferation. 
 Regardless of the inhibitory mechanism, immunosuppressive activities of 
H. pylori mediated by VacA are likely to be physiologically important during 
infection. Indeed, gastric biopsies from H. pylori-infected individuals consistently 
demonstrate Th lymphocytic infiltration (134, 279) and antigen-specific Th cells 
have been detected in the gastric mucosa (134, 295). Nevertheless, H. pylori is 
still able to evade the immune response and establish persistent infection. Given 
the importance of Th cells in mobilizing immune responses against extracellular 
bacteria, including H. pylori, our findings indicate that VacA can inhibit the clonal 
expansion, and thus the acquisition of effector functions of T cells that have 
already been activated by H. pylori antigens (325).  
 Future studies have been initiated and will continue to use VacA as an 
immunological tool to further understand the molecular regulation of Th cell 
clonal expansion as driven by IL-2. Specifically, human Th cells intoxicated with 
VacA will be further scrutinized for their biochemical signaling responses to IL-2 
as compared to normally growing untreated cells or those treated with non-
functional VacA mutant toxins. In addition, gene expression profiles of VacA 
intoxicated Th cells will also be evaluated in efforts to identify changes in cell-
cycle-related gene expression that accompanies the VacA-induced attenuation of 
IL-2-driven cell-cycle progression. Together, these studies will have implications 
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in understanding the molecular mechanisms governing Th cell clonal expansion 
in response to antigenic activation and will garner further elucidation of the 
fundamental processes that regulate cell growth.  
 In summary, the activation, differentiation and resultant function of Th cells 
responding to pathogenic microbes specifies the efficacy and long-term viability 
of human immunity and can also directly influence the manner by which Th cells 
interact with invading pathogens. By decoding the physiologic programs of 
human Th cell differentiation and elucidating the mechanisms whereby microbes 
hijack normal Th cell function to evade host immune responses we may be able 
to therapeutically manipulate these processes to better protect against infectious 
human diseases and ameliorate immunopathologies.    
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